aid,authorProfileId,name,authorTitle,pid,text,label
6d1cf509-8cb8-4eeb-8eda-e2c2c26b696b,shane-hinze-a62b86266,ShaneHinze,Direct Sales Respresentatie,c15a3132-1cbb-40e5-aa48-e952a3a1c3aa,"I‚Äôm very happy to announce I will be starting a new role with #AstraZeneca and Syneos Health selling Farxiga and helping people with chronic kidney disease!
I‚Äôm very grateful to grow and learn in this new role!",['Pharmaceutical Representative']
5aa7d614-6fa7-4711-9292-91c23490aebb,cchrvala,"CaroleChrvala, PhD","Epidemiologist with a passion for medical writing, research, and strategic consulting for the healthcare industry",01469572-ddbd-4e4a-8934-11b6182dd0fb,A 60% reduction is certainly of clinical as well as statistical significance. It is notable that only 9.6% of patients were treated with Paxlovid.,['Healthcare Provider']
333f31f4-360f-4c67-be37-943cbe9b1d85,gergely-szoter,"GergelySzoter, MBA",Life Sciences | Biotechnology | Bioprocessing | Market Intelligence | Market Insights | Driving Revenue Growth | Leading Sales | Leadership | Strategic Accounts | Energy | Automation | Fortune 500 experience,0897dc93-48e2-4e25-868d-33c2f19f1b6d,"02.11.2024. ""The only way to discover the limits of the possible is to go beyond them into the impossible."" ‚Äì Arthur C. Clarke.

Another earnings season, another set of reports from the leading players in the market. There were some winners and losers in the last quarter. 

This week's highlights are the following:

1Ô∏è‚É£ Bristol Myers Squibb's earnings surge and guidance raise: Reported adjusted EPS of $1.80 versus $1.49 expected; revenue of $11.89 billion surpasses estimates, driven by Eliquis and growth portfolio #drugs like Reblozyl and Opdivo. The company raised its full-year revenue guidance, expecting sales to increase by around 5%.

2Ô∏è‚É£ Merck's Keytruda drives Q3 performance: Adjusted EPS of $1.57 beats expectations; revenue reaches $16.66 billion. #Keytruda sales increased 17% to $7.43 billion, offsetting an 11% decline in Gardasil sales due to lower demand in China.

3Ô∏è‚É£ Pfizer's revenue surges amid #Covid product demand: Adjusted EPS of $1.06 surpasses estimates; revenue of $17.7 billion beats forecasts. #Paxlovid and Covid vaccine sales boosted earnings, but the company faces activist investor pressure to improve capital deployment.

4Ô∏è‚É£ Eli Lilly's shares dropped despite solid #demand. The company Missed Q3 earnings estimates due to inventory adjustments, and Zepbound and Mounjaro sales fell short despite a 25% increase in prescriptions. Therefore, the company lowered its full-year adjusted profit guidance.

5Ô∏è‚É£ Biogen raises profit guidance on Leqembi #sales: Adjusted EPS of $4.08 beat expectations, and revenue of $2.47 billion exceeded estimates. The Alzheimer's drug Leqembi generated $67 million in sales, exceeding projections and helping offset declines in multiple sclerosis products.

6Ô∏è‚É£ Smith & Nephew cuts #forecast amid China demand slump: Shares fell 12% after lowering its revenue growth forecast due to unexpectedly weak demand in China, impacted by the country's volume-based procurement program affecting #medicaldevices.

7Ô∏è‚É£ Teva fined ‚Ç¨463 million by EU for #Antitrust Violations: The European Commission fined Teva for unfairly disparaging a rival multiple sclerosis drug and manipulating patent protections for its product, Copaxone.","['Healthcare Provider', 'Pharmaceutical Representative', 'Regulator']"
c1347a85-e947-46a8-9ea4-0e308c5cb6eb,rachidakiki,"RachidAKIKI, MD, MBA",Head of Regulatory & Clinical Affairs,f75f4037-e69e-4bfd-9001-4159a728c518,"Pfizer‚Äôs financials just got a powerful boost. In Q3 alone, they reported a whopping $4.5 billion in net income‚Äîan impressive leap from a $2.4 billion loss last year‚Äîand revenue reached $17.7 billion, surpassing forecasts. Much of this growth is powered by high demand for their Covid-19 vaccine and Paxlovid treatment.
But there‚Äôs more exciting news! Keep an eye out at Walmart and CVS for the latest self-test kits by 2San, now on shelves and ready to make at-home testing easier than ever. Perfect for peace of mind, these tests bring cutting-edge health solutions right to your fingertips. Don‚Äôt miss it!
#Pfizer #Q3Boost #2SanSelfTests #Walmart #CVS #AtHomeTesting #HealthcareInnovation

4o","['Regulator', 'Pharmaceutical Representative']"
8d69b4e7-39d0-4b84-9cda-bdac181853b8,bryce-platt,"BrycePlatt, PharmD",Consultant Pharmacist | Drug Pricing and Policy | Pharmacy Benefits | Passionate about Aligning Incentives to Benefit Patients,0030670c-4ff4-4569-9ad7-b2d13b7ddca7,"Community pharmacy is transforming. The pharmacy model needs to evolve to match that transformation.

---

CVS Health recently released their fall ""Rx Report"" looking at the trends in community pharmacy.

""Based on a survey of #pharmacists, pharmacy technicians, and consumers, the annual Rx Report analyzes industry trends in community pharmacy, including growing patient trust and increased demand for pharmacy care, as well as key opportunities to evolve and better support pharmacy teams.""

---

The first attached image from the report shows some statistics about how pharmacies are viewed in the community.

According to the survey, community pharmacies have high consumer trust and often are the most frequent ways that patients access healthcare.

Even if digital communication options are available, the majority of consumers prefer talking to pharmacy staff in person. Digital options seem to be best used as a supplement, not the foundation of patient interaction, according to the survey.

---

The second attached image illustrates that pharmacists and patients are ready for more healthcare inside the local #pharmacy.

This and other surveys have consistently shown pharmacists are able and willing to perform more healthcare services than they currently are, but it isn‚Äôt clear in the report if consumers want their pharmacist to perform more healthcare services or if they want the convenience of having more healthcare services available at their local pharmacy.

Specifically mentioned by consumers were a desire to have services in their local pharmacy like:

-Diagnostic tests for flu, strep throat, HIV, etc.
-Monitoring services like blood pressure testing (I would personally add A1C, blood glucose, and cholesterol testing)
-Vaccinations
-Pharmacists prescribing limited medications (e.g., birth control, naloxone, Paxlovid)

---

Community pharmacies are valuable access points for #PublicHealth

Many people value their community pharmacy and there seems to be demand to have the pharmacy offer more services beyond just filling prescriptions.","['Healthcare Provider', 'Payers and Insurers', 'Pharmaceutical Representative', 'Regulator']"
b9512f5e-ca92-42a5-b64d-f4546a5e6368,hilina-tsega-b7124b2b0,HilinaTsega,Senior Technical Advisor/TA on COVID-19 and other emergency response at Ethiopian Public Health Institute/PHEOC,de75eea2-b2bc-413c-961b-4d069e999612,"On October 29-30, 2024, in Adama, we conducted a review meeting in collaboration with the Ministry of Health, EPHI, and stakeholders to assess the pilot implementation of the COVID-19 test-to-treat program, including Paxlovid drug administration, across 17 health facilities.","['Healthcare Provider', 'Regulator']"
ca90ecea-0720-486d-91e7-607ddc59edf3,dr-e-shyam-p-reddy-03ab9922,Dr E. Shyam P.Reddy,"GCC Distinguished Cancer Scholar, Professor and Director, Cancer Biology Program, Department of OB/GYN, Morehouse School of Medicine, Atlanta, Ga 30310",b672c19f-81a2-4ab5-a202-5dada166b039,"new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.
The study¬†was published today in¬†Scientific Reports¬†and adds to the understand of the usefulness of Paxlovid in the Omicron-variant period.
Using electronic health records from the Dubai Health Authority (DHA) hospitals and clinics in the United Arab Emirates, the authors of the study compared outcomes of patients who received Paxlovid to those who did not receive any antiviral treatment for COVID-19 seen from May 22, 2022, to April 30, 2023, at any DHA-affiliated hospitals and clinics.
The study defined long COVID as continuous or new symptoms present 28 days or more following acute COVID-19 infection, based on physician notes.¬†
In total 7,290 non-hospitalized adult COVID-19 visits, including 672 patients who received Paxlovid and 6,618 patients who received no antiviral treatment, were included in the study. Almost half of the patients in both groups had received two doses of the COVID-19 mRNA vaccine (45% in the Paxlovid group, and 48% in the no-treatment group), the authors said.
1.1% in Paxlovid group hospitalized¬†
A total of 170 (2.3%) COVID-19-related hospitalizations lasting‚Äâmore than 1 day were observed over a 28-day period. These included 8 (1.1%) in the nirmatrelvir-ritonavir group and 162 (2.4%) in the no-treatment group.
After adjusting for factors, Paxlovid was associated with a 61% lower risk of hospitalization (adjusted hazard ratio [aHR], 0.39; 95% confidence interval [CI], 0.18 to 0.85).¬†
During a 90-day follow up, 208 patients (2.8%) experienced long-COVID symptoms that prompted them to see a physician. Paxlovid was associated with a 58% reduced risk of developing such symptoms during that period (aHR. 0.42; 95% CI, 0.19 to 0.95).","['Healthcare Provider', 'Regulator', 'Pharmaceutical Representative']"
06bfa3fb-7c97-444c-8b50-f0b4b7c8582c,dhyanesh-shah-5b59a2285,DhyaneshShah,Student at Conestoga College,de1d8b41-6a5f-4a38-9b51-cc96a301e8b3,"Pfizer‚Äôs strong sales growth, driven by Paxlovid, is a big win amid market challenges. Impressive resilience and a boost for Albert Bourla leadership!",['Pharmaceutical Representative']
cc84fee3-f998-4bb0-9275-5d078ab5c1ad,pallavi-madhiraju-54053a87,PallaviMadhiraju,Content Writer Self Employed Crafter Jewellery Maker Entrepreneur,f2fae86c-750d-4f46-a24b-dbc44eebdcc8,Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost #Pfizer #Earnings #Seagen #Vyndaqel #Eliquis #Comirnaty #Paxlovid,['Patient']
9e88f821-b00d-4fc7-8127-f6b28893828d,pranavghai,PranavGhai,"Calcbench, Inc",a8cee657-ac25-4ee3-a6ca-69c60b6517e6,"Pfizer's segments are rich with information.  Here's a time series of drug sales from our time series template on Calcbench.  We captured 5 significant drugs in this chart including some from the #earnings report issued this morning (October 29).  

In the chart in the comments we included #paxlovid which, as you will see, destroys the scale of the graph because of it's volatile (seasonal) sales. 

#pharma
#revenues
 #segments",['Pharmaceutical Representative']
112f3071-2e03-4c0d-9e8b-20003adbe52c,gvoskop,"GeorgeVoskopoulos, PhD","Associate Professor,European Studies, f.Department Head,f.Erasmus Acad.Coordinator,f.JMonnet Thematic Research Coordinator. EX-COMMUNICADO for Standing Up to forced KAKISTOCRACY in a regime-structured UoM, Gr",795726b6-3449-41a4-9994-41e9a5d9689f,"Pfizer profits up on COVID treatment sales as it faces off with activist
""¬†Pfizerreported higher-than-expected profit on Tuesday due to strong sales of COVID treatment Paxlovid, an important win for Chief Executive Albert Bourla as he faces down activist investor Starboard"".
https://lnkd.in/dwmSqaFn",['Healthcare Provider']
1f428b5d-5fb6-4be2-8c33-bf5c2e7b40f4,taylor-king-138b69296,TaylorKing,Social Media Community Manager and Media Relations,59e7b3b8-056b-4316-8dfc-83f36ed553be,"Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales

Pfizer reported third-quarter revenue and adjusted profit that blew past expectations.

The company hiked its full-year outlook as its Covid vaccine and antiviral pill Paxlovid helped boost sales.

It is a critical quarterly report for Pfizer, which is grappling with a proxy battle waged by the activist investor Starboard Value.",['Regulator']
63211c0b-c65d-4b26-b20d-0d9e02f514cb,dan-sheehan1,"DanSheehan, MBA, MS",Financial Markets Strategist / Financial Advisor | PhD Candidate in Business-Finance | MS in Data Analytics | MBA | Former D1 Collegiate Golfer at Augusta University,7527e224-41b8-4184-88da-0fa902f4a56b,"üìä Pfizer Q3: Strong Rebound as Non-Covid Portfolio Shines üíâ

Key Numbers:

EPS: $1.06 vs $0.62 expected
Revenue: $17.7B vs $14.95B expected (+31% YoY)
Net Income: $4.47B vs -$2.38B YoY

2024 Guidance Raised:

EPS: $2.75-$2.95 (up from $2.45-$2.65)
Revenue: $61B-$64B (up from $59.5B-$62.5B)

Portfolio Performance:

Covid Products
- Paxlovid: $2.7B (including $442M government stockpile)
- Vaccine: $1.42B (+9% YoY)

Non-Covid Growth (+14% operational):
- Seagen portfolio: $854M
- Vyndaqel: $1.45B (+62% YoY)
- Eliquis: $1.62B (+8% YoY)
- RSV vaccine: $356M (exceeding $255.4M estimate)

Analysis: Pfizer demonstrates strong execution beyond Covid, with significant growth in its core portfolio. The successful integration of Seagen acquisitions and strong performance in newer products like RSV vaccine suggest the company's strategic investments are beginning to pay off. Cost-saving initiatives remain on track for $4B in savings by year-end.

#Pfizer #Healthcare #Pharmaceuticals #Earnings #Biotech #Covid #WealthManagement #FinancialPlanning",['Regulator']
e6b63fd5-d562-4c83-9b87-4e2187f0e386,pharmaceutical-business-review-international-a7b54bb5,Pharmaceutical Business ReviewInternational,48K I Global Medical Journal I 18th Year I Houston I Istanbul I Clinical Trials I Innovative Therapies I Patient Journey I Ethics,7d6adeb6-2d27-43e2-b9d4-1263df73e7fc,"Pfizer reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance for both Revenues and Adjusted diluted EPS. 

The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer‚Äôs R&D pipeline can be found at www.pfizer.com. 

EXECUTIVE COMMENTARY 

Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: 

‚ÄúWe delivered another strong quarter of results as we continued to execute with discipline, strengthen our commercial position and advance our pipeline. I am pleased with the performance of our product portfolio in the third quarter as we continued to achieve exceptional growth with our Oncology products, including strong revenue growth contributions from Padcev, Xtandi, Lorbrena and Braftovi/Mektovi, and as we delivered on heightened demand for Paxlovid during the recent COVID-19 wave.""

‚ÄúOur performance through the first three quarters of the year is the result of our focus on our most important strategic priorities. I‚Äôm confident that we will deliver on our financial commitments in 2024 and that we are well positioned to continue advancing scientific breakthroughs meaningful to our patients and our company, as well as creating long-term shareholder value, in the years to come.‚Äù

Dave Denton, Chief Financial Officer and Executive Vice President, stated: 

‚ÄúWe are extremely pleased with the strong 14% operational revenue growth of Pfizer‚Äôs non-COVID products in the third quarter. This follows our strong first-half performance, which demonstrates our continued focus on commercial execution and confidence in our ability to deliver on our financial guidance this year. Importantly, we believe our ongoing cost reduction efforts set the company on a path toward future margin expansion.‚Äù
#financialresults #Pfizer","['Healthcare Provider','Patient']"
bf10362c-39d0-47f8-9abe-46f66940c264,cedricbignet,C√©dricBignet,"ERP transformation expert | Global Finance Director | certified Project Manager | ERP strategy (SAP S4/Hana, Microsoft D365)",2e786829-78ec-4ff6-a870-74371c207976,"ü§ñ In today‚Äôs fast-evolving pharmaceutical landscape, AI and digital transformation projects are not merely enhancements but necessities for staying competitive, efficient, and responsive to patient needs.

As the industry grapples with complex challenges, from accelerating drug discovery to managing massive data loads, AI-driven initiatives have become crucial for optimizing operations, reducing costs, and delivering better patient outcomes. Transformation projects, particularly those integrating AI, machine learning, and automation, are helping pharma companies streamline everything from R&D to supply chain management, pushing the industry toward faster, more precise, and scalable solutions.

Embracing these technologies enables companies to stay at the forefront of healthcare innovation, as shown by industry leaders like Pfizer, Roche, and Novartis, who are investing in digital-first strategies to tackle real-world healthcare challenges.

üíä Pfizer: Leveraged AI in clinical trials for COVID-19 treatments, achieving a 50% reduction in clinical trial data processing times. AI also supported the development of Paxlovid, reducing key steps in the supply chain cycle by 67%, allowing for 20,000 extra doses per batch‚Äã


üíäRoche: Through its partnership with Recursion Pharmaceuticals, Roche aims to use AI for faster drug discovery and data-driven clinical decision-making. The company has focused on predictive analytics to streamline R&D and ensure efficient patient care delivery by integrating real-world data.

üíäNovartis: Operating over 150 AI projects, Novartis has reduced operational costs and improved drug discovery speed. The collaboration with Microsoft aids in integrating AI-driven insights across R&D and clinical processes to accelerate development and bring down costs‚Äã.

üíäSanofi: Uses machine learning with partners like Aily Labs to optimize its drug discovery pipeline, reducing time to identify compounds for clinical trials. Additionally, the AI-driven insights aid in predicting patient responses to improve safety outcomes in early drug development phases.

üíäAstraZeneca: Automated patient trial matching and used AI for demand forecasting, reducing trial duration by 5-10% and enhancing patient engagement. With AI-driven precision medicine, AstraZeneca has focused on subpopulation targeting to optimize clinical trials‚Äã.",['Regulator']
77543d98-4bdb-480e-b131-3d0c768fd92e,jodianpinkney,JodianPinkney,Infectious Diseases Physician,acfdf8ab-2078-4508-acbf-270a31987eee,"Please join me on Friday, November 1, 2024, as I moderate the ACP Early Career Physician Journal Club, featuring Dr. Mark Siedner, senior author and special guest speaker, in a discussion on SARS-CoV-2 rebound with Paxlovid. Looking forward to an engaging session!",['Healthcare Provider']
7584f25b-226d-41fa-a5f5-bc9de3c9d44c,karen-huerta-vargas-9592b92b,KarenHuerta Vargas,MBA / Country Brand Lead Paxlovid,0247fd94-c3fe-4119-991d-52d6d124acac,"Im happy to share that I had the opportunity to attend the Paxlovid Masterclass in Berlin! 

This event was a fantastic chance to learn about the latest updates on COVID-19 and to exchange experiences with healthcare professionals from around the globe. I was particularly thrilled to connect with Mexican opinion leaders. 

It was also great to collaborate with my peers and colleagues from Taiwan and Singapore. The exchange of knowledge and insights was very enriching. With this event we are reinforcing our collective commitment to advancing patient care.

 #Paxlovid #COVID19 #GlobalHealth #Networking #PfizerProud #COVID19Treatment",['Regulator']
dd255a36-502e-48cf-8945-1016d40dbe84,oluwabusolami-lampejo-603475334,OluwabusolamiLampejo,Health advisor/ professionalist. Pharmacologist,d9ec61e3-3892-4d29-8edc-fb165dac5223,"The United Nation is our one great hope for a peaceful and free world _ Ralph Bunche.
    
  Hiiiiiiii dearies....... It's  the United Nations day and also Day 4 of LinkedIn challenge.....who is excited üòäüòäüòäüòä????.  Join me as l unravel interesting facts about the United Nations.
        

   The United Nations is an international organization founded in 1945 after the second world war by 51 countries committed to maintain international peace and security, developing friendly relations among nations and promoting social progress, better living standards and human rights. 

  There are various healthcare system within the United Nations which includes World Health Organization (WHO), United Nations Children's Funds( UNICEF), United Nations Population Fund (UNFPA), Joint United Nation Programme on HIV/AIDS ( UNAIDS) and United Nations Development Programme (UNDP).


    If given the opportunity, l would love to work with the World Health Organization. Setting up a standard healthcare system for patients has always been my dream, the smile and satisfaction from a patient is what gives me joy.
  

   Since the foundation of WHO in 1948, the world has experienced countless public health challenges threatening our health and well-being. However, numerous obstacles have been overcomed and remarkable advancement have been made in medical science, health care and overall population health.



   The United Nations since its inception, has been actively involved in promoting health worldwide. At the outset, it was decided that WHO's top priorities would be malaria, women's and children's health, tuberculosis, venereal disease, nutrition and environmental pollution. Many of these remain on WHO's agenda today, in addition to relatively new disease like HIV/AIDS, Diabetes, Cancer, SARS( Severe Acute Respiratory Syndrome), Ebola an Zika disease.



   During the COVID-19 outbreak, the WHO together with the FDA( Food and Drug Administration) established programs allowing clinicians to gain access to investigational therapies during the pandemic. Antiviral drugs like Remdesivir, Tocilizumab, baricitinib, monoclonal antibodies, paxlovid was approved by the FDA in treating COVID-19. 



    Have you ever thought about a world without disease....... do you think it is possible to eradicate disease in the world we are today?. Feel free to connect and please comment in the comment section.


  #Day4
  #20daysconsistencychallenge
  #Doitscared","['Healthcare Provider', 'Pharmaceutical Representative']"
1dd56bbb-f5fd-4253-affa-71f4c5dab9e7,mrokern,MarkOkern,Customer obsessed | Splunker,2fa90e8d-a313-4e47-ba95-0da2c2a9f5af,"Need proof that culture isn‚Äôt a building? 

I‚Äôm currently sitting here with Covid‚Ä¶seemingly the cost of travel these days, sadly. Courtesy of Paxlovid I‚Äôm doing ok. 

Texts and Slacks have rolled in all week. 

Manager. My reps. My peers. Advisers on our team. Cisco colleagues too, not just Splunkers. 

And it‚Äôs not ‚Äúhey I need you to work while you‚Äôre sick‚Äù, it‚Äôs ‚Äúhow are you feeling and can we cover anything for you?‚Äù

THAT is a healthy culture. No cubicle required. 

Look‚Ä¶some industries and teams, RTO makes sense. I get it. And I‚Äôve had roles where that‚Äôs been the case. 

But blindly throwing out ‚Äúculture‚Äù as a reason is nonsense. It shows insecurity, and believe me, your employees will spot weak leadership every time.",['Patient']
6a9aa05b-9ee9-4e62-aa37-fc0222b6ca54,gurinder-s-sidhu-md-mha-mba-862080211,"Gurinder S.Sidhu, MD, MHA, MBA","U.S. PAXLOVID Medical Lead, Senior Director at Pfizer",777f5e28-baf6-4c18-8b1f-1e40f0f8c3f8,"I‚Äôm happy to share that I‚Äôm starting a new position as U.S. PAXLOVID Medical Lead, Senior Director at Pfizer!",['Regulator']
35f7b09c-827b-4f4f-b561-9164fca0b65a,stephen-young-m-d-2177b1241,"StephenYoung, M.D.","Physician with 35 years of medical practice in critical care, geriatrics and palliative care now providing healthcare advocacy services to all patients grappling with serious illness.",13d67383-0822-42fc-b7d0-98edc15dff11,"10/21/24    Healthcare advocacy - Long Covid - Chronic Fatigue Syndrome

Advocates often provide support to patients grappling with Long Covid/Post-acute Sequelae of Covid (PASC) symptoms including fatigue, weakness, shortness of breath, dizziness, palpitations and brain fog - recent flurry of studies and articles shed light on efforts to prevent and treat PASC:
¬∑¬†¬†¬†¬†¬†¬†Journal of Infection 2024 Jiang J, et al ‚Äì summary of observational studies suggests that early nirmatrelvir-ritonavir (Paxlovid) during acute Covid may reduce the risk of PASC although definitive evidence (from randomized controlled trial) is not available. Fortunately, the risk of PASC (without anti-viral medication) has declined from 10% early in the pandemic to current 3.5%. However, the stakes remain high as those afflicted by PASC often have an unrelenting course. 
¬∑¬†¬†¬†¬†¬†¬†JAMA Int Med 2024 Geng LN, et al ‚Äì in patients with PASC, a 15-day course of Paxlovid disappointedly did not reduce symptoms.
¬∑¬†¬†¬†¬†¬†¬†At present, there‚Äôs neither cure nor validated treatment of PASC yet many practitioners view this malady as similar to Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) and base their treatments of PASC upon what seems to work in patients with CFS/ME. https://lnkd.in/eThJsiaY ¬†¬†¬†
¬∑¬†¬†¬†¬†¬†¬†Regarding the cause of PASC - a highly sensitive test finds that approximately one-half of patients with PASC have residual virus hidden away long after their acute illness has resolved - https://lnkd.in/eCArTgx7 
¬∑¬†¬†¬†¬†¬†¬†Yet, another study ‚Äì Annals Int Med 2024 Montaz-Rath M et al concluded that patients with PASC cannot be identified by routine blood testing (e.g. blood counts, chemistries).
Take home points:
¬∑¬†¬†¬†¬†¬†¬†Vaccination remains key preventive measure
¬∑¬†¬†¬†¬†¬†¬†Patients with acute Covid should consult with their primary care provider to individualize their risk of developing PASC and whether or not to proceed with Paxlovid in an effort to reduce this risk.
¬∑¬†¬†¬†¬†¬†¬†At present, there‚Äôs neither definitive cure nor treatment of PASC however many clinicians are drawing from what‚Äôs known about caring for patients with CFS/ME to mitigate PASC-related debility ‚Äì management of patients with PASC involves both pharmacologic and non-pharmacologic approaches and is tailored according to symptoms. 
¬∑¬†¬†¬†¬†¬†¬†A leading theory regarding the cause of PASC is that some patients, following recovery from an acute Covid illness, may have lingering virus which activates the immune system and this inflammation may lead to multi-organ dysfunction. 
¬∑¬†¬†¬†¬†¬†¬†Paxlovid has not been shown to effectively treat PASC yet ongoing research may identify sub-groups of patients with PASC who would benefit from a longer course of Paxlovid. 
¬∑¬†¬†¬†¬†¬†¬†However, if harboring the Covid virus is the cause of PASC in certain patients, what‚Äôs causing PASC in those without residual virus?",['Healthcare Provider']
21292b88-a734-437b-a791-f342458ac7b4,nastaran-hoseini-895ba2332,NastaranHoseini,ÿ™ÿ≠ÿµ€åŸÑ ÿØÿ± ÿØÿßŸÜÿ¥⁄ØÿßŸá ÿßÿ≤ÿßÿØ ⁄©ÿ±ÿ¨,71c001b2-33e9-4977-9615-ac09c33f203e,"COVID-19: Treatments and Medications 

While most people with COVID-19 have mild illness and recover at home, some people require medical care and treatment. Treatments for COVID-19 should always be prescribed by a doctor. If you have COVID-19 symptoms, contact a doctor right away and do not delay treatment. 
In addition to COVID-19 treatments, a doctor may recommend the following to relieve symptoms: 

‚Ä¢ Medications to reduce fever (such as acetaminophen or ibuprofen) 

‚Ä¢ Drinking water to stay hydrated 

‚Ä¢ Getting plenty of rest to help your body fight off the virus 

Talk to a doctor to see which COVID-19 treatment or medication may be right for you.¬†They can help determine if you are eligible.

Test to Treat program
Department of Health Services (DHS) is partnering with the federal government on a new Test to Treat program as part of the¬†National COVID-19 Preparedness¬†Plan. Through this program, people have access to ‚Äúone-stop‚Äù test and treat locations. Select pharmacies and federally qualified health centers will provide rapid COVID-19 testing. If the person is qualified for treatment, a doctor will offer the medication on the spot.¬†See Test to Treat locations.
Oral antiviral drugs authorized for treatment of COVID-19 

If you have symptoms of COVID-19, oral antiviral pills can help prevent severe illness. In December 2021, the U.S. Food and Drug Administration (FDA) authorized two oral antiviral medications for people with mild to moderate COVID-19 symptoms who are risk for severe illness: 

‚Ä¢ Paxlovid 

‚Ä¢ Lagevrio (also called molnupiravir) 

These medications stop the virus from replicating in your body which reduces your risk of severe COVID-19 illness, hospitalization, or death. These medications are limited to people who are at¬†high¬†risk¬†of developing severe COVID-19. Both Paxlovid and Lagevrio must be started within the first five days of symptom onset.
A third antiviral treatment called Remdesivir is FDA approved for people diagnosed with COVID-19. This is an intravenous treatment that is available at some health care facilities. This medication is not distributed by the federal government, and we do not track its availability on our maps.
Lagevrio(molnupiravir)
Lagevrio is an oral antiviral medicine that can be used to treat mild to moderate COVID-19 symptoms.
Paxlovid
Paxlovid is an oral antiviral medicine that can be used to treat mild to moderate COVID-19 symptoms.
Remdesivir 
Remdesivir is an intravenous medicine that can be used to treat mild to moderate COVID-19 disease. 

How does remdesivir work?+ 

Am I eligible for remdesivir?+ 

How can I get remdesivir?+ 

If I take remdesivir, do I still need to isolate?+

Get vaccinated against COVID-19 

COVID-19 treatments and medications should not be used as replacements for prevention measures such as wearing a mask and vaccination. For the best protection against COVID-19 and circulating variants, get vaccinated and get your booster dose of COVID-19 vaccine.",['Healthcare Provider']
ab9dcd10-a4d2-4236-8731-7dfd382de64d,funsho-akinyele-604a9018a,FunshoAkinyele,"UI/UX DESIGNER, GRAPHIC DESIGNER, WORDPRESS WEB DEVELOPER, TRANSCRIBER",a6c2b494-67e1-4d4e-b758-0e4ebd378c8d,"Changes in Paxlovid coverage raises concerns about affordability, access in¬†N.B.",['Patient']
85f68b61-dab6-4620-8b59-0d080043144a,daryldarby13,DarylDarby,Award Winning District Sales Manager / Sales Management / Team Builder / Product Launch,0fad7a3a-33f5-4f89-9eb2-58fafaabff07,"Excited to announce that I've taken on a new role as Area Business Manager at Pfizer! I now oversee a team of 12 Territory Representatives dedicated to promoting Paxlovid, Nurtec ODT, and Lucira under the Inizio Contract. #NewBeginnings #Pharmaceuticals",['Regulator']
460e9d0b-4052-4cff-b76e-6a2dd78b921d,alirizvi1,Syed AliRizvi,President at SPS ALFACHEM,f56b24ed-75e3-494b-b014-7d5930d8deb6,"study led by researchers at Mass General Brigham offers insight into long COVID, suggesting that nearly half of patients may still have hidden viral reservoirs in their bodies long after the initial infection. The study used ultra-sensitive blood tests to detect fragments of the virus in 43% of those with long COVID symptoms. This discovery supports the theory that lingering viral particles may be causing the condition, though it‚Äôs not the sole cause. The research could lead to better treatments, like the NIH-funded trial testing the antiviral drug Paxlovid on patients with viral remnants.",['Regulator']
656c7105-f4f1-4a92-ac2a-89fd260a7628,mel-berger-99884519,MelBerger,Biopharmaceutical Expert at Berger Consulting LLC,cc425be9-f505-450a-856a-0ba60dd6dba4,"Anthony Fauci: A Mosquito in My Backyard Made Me the Sickest I‚Äôve Ever Been
(Printed in New York Times: Oct. 13, 2024)


After I spent more than 50 years chasing and fighting viruses, one fought back and nearly took me down. I speak of the West Nile virus, delivered by the deadliest animal on the planet: the mosquito.

I got infected not during any of my international trips over the years but most likely while I was outside my home in Washington, D.C. In mid-August I was feeling weak and exhausted but attributed it to a recent bout with Covid-19. Though I tested positive for Covid over a month prior, I experienced a rebound of symptoms after taking the treatment Paxlovid. Perhaps I was still experiencing lingering symptoms that would eventually resolve.

Not so. Instead, I began to experience unexplained severe fatigue and exhaustion, culminating in my admission to a hospital on Aug. 16, delirious and incoherent, with a temperature of 103 degrees. I remember little of the five and a half days that I spent in the hospital, except that I had never felt so ill in my life. My physicians assumed that I had sepsis and treated me with antibiotics. That changed the next day when blood tests revealed that I had West Nile virus.

There is no treatment for West Nile virus disease, and I was left to deal with its toll on my body. It was terrifying....
Fortunately, over a few weeks, slow improvement began. I. I am on my way to a total recovery, but it has been a harrowing experience.",['Pharmaceutical Representative']
2269001c-22ab-43b6-ad30-48331a31fdc3,marianne-ritchie-gordon-m-d-a01b3a8,"Marianne RitchieGordon, M.D.","Host, ""Your Radio Doctor"" at Talk Radio 1210 WPHT",7a13a011-6df9-4b6a-a88d-8a55dabbbf96,"Is COVID still a threat?  Does the 2024/2025 season vaccine cover the current strain that is circulating?  Hear answers to these and all your important questions when you listen to the podcast from our show that aired on
Saturday, October 12.  www.audacy.com and search Your Radio Doctor.
#Independence Blue Cross #Audacy, Inc. #WPHT Radio #Children's Hospital of Philadelphia #Penn Medicine, University of Pennsylvania Health System",['Healthcare Provider']
094d4d81-ee5b-4424-90e3-3ec839175ece,suzan-jackson-8436878,SuzanJackson,Author and Freelance Writer,763f4671-41ed-4c76-bd3f-a456d90a6c94,"What To Do If You get COVID - my new post covers various treatment options like Paxlovid, including both research and my own experiences. While it is focused on those with #MECFS & #LongCOVID, it's useful for ""healthies,"" too, to prevent long-term effects:
https://lnkd.in/e67PEhqw",['Patient']
d53c79f2-b8e6-4b55-9159-cba634ac5354,michael-rynne-766a9887,MichaelRynne,O&E Solutions Ltd and CLL Ireland,a16aa17a-8d74-4659-afe5-edea19fefe96,"It's about to become even more difficult to access paxlovid in Ireland as health policy makers shamefully  decide to no longer fund the drug.
A warning that other countries may be considering this move.


https://lnkd.in/eQ6XiuYU",['Patient']
a30f4e5d-38a8-4f85-b153-82908ee8940f,jan-rynne-aa6bb81a9,JanRynne,Passionate about patient advocacy,74b56056-38c3-484d-9d5e-01d658b20fd7,"This cannot be allowed to happen. As a #cll patient who dodged Covid for 4 years, I was very grateful to be able to access the Paxlovid anti-viral when I needed it last June. Timely access to this treatment significantly aided my recovery. We must be supported by our government and health service in our navigation of our immune challenges. We cannot be forced to live life on the fringes due to access or cost implications.
As Ireland moves forward in this post pandemic world, our Health Service Executive  and policy-makers must be cognizant of a cohort of society who relies upon supportive treatments like Paxlovid
We must have equitable access to anti- viral treatments when we need it to enable us to live our lives as fully as possible. Surely this is a bare minimum in our democratic society.
CLL Ireland 
Michael Rynne 
CLL Advocates Network 
#nothingaboutuswithoutus","['Patient', 'Regulator']"
2837c40b-b8bc-4ee0-8584-9c9b55f116df,obiebukadavid,Obi EbukaDavid,Founder & CEO Autogon AI || YC Alumni || Forbes/GSE 2020 || IEEE Member (AI won't replace you. Someone using AI will),d8b9823b-a2ff-444f-a3ac-f0c4b8d6015b,"üî¨ Small Wins Against COVID-19 with Big AI Innovations üî¨

COVID-19 treatments like Remdesivir and Paxlovid have helped, but our AI model is taking it further even beyond for SARS-CoV-2 and beyond. We‚Äôve generated molecules with higher potential across multiple protein targets, showing promising results in binding affinity and drug-like properties.

From small victories on COVID-19 to amazing breakthroughs on other disease targets, Medgnosis GenAI continues to innovate. Explore more reports at https://medgnosis.ai/

Here is our latest press release: https://lnkd.in/d2i2-Xf2

#COVID19 #AIinHealthcare #DrugDiscovery #MedgnosisAI #ProteinTargeting Pfizer, Moderna, Johnson & Johnson",['Regulator']
91e6002c-b042-4808-8208-3c74bab03112,jonmichaeli,JonMichaeli,GTM & Commercial & Exec | Health/Med Tech | UAV/UAM ex-Zipline ex-Matternet,5c0abb1d-8638-44f2-9a2d-bfbd746c69af,"This is nice progress, but we all know the frustration of false negatives from antigen tests. 

The first time I had #COVID, I tested negative, so I went to work out to sweat out the toxins (which I often do with the common cold). Two days later I felt horrible and tested positive‚Ä¶and hence started Paxlovid quite a bit later. That bout of COVID was likely far worse and lasted far longer than needed. 

What we lack in the #hometesting market are low cost highly sensitive #moleculartests for a variety of #infectiousdiseases. #diagnostics #homehealth #healthathome #telehealth RT MicroDx","['Healthcare Provider', 'Regulator']"
ada07c99-fda1-4c26-8008-df1b4077dec7,jlevinscherz,JeffLevin-Scherz,"Population Health Leader, WTW Health & Benefits; Assistant Professor, Harvard Chan School of Public Health",2b67ed02-206f-4fca-92b8-be26174510e5,"Today in #Employer Coverage: Short posts on hospital #consolidation, #GLPs and overdose, nasal #COVID vax, paxlovid, and KFF annual survey.",['Healthcare Provider']
7a7ea738-38e2-4529-8537-edb3bb006b90,nuno-vale-09029b40,NunoVale,"Associate Professor, Faculty of Medicine, University of Porto",d6a3a6b2-741e-43bb-905c-59b43fb383d8,"A new approach to repurposing Ritonavir for Personalized Medicine in Oncology. 

Ritonavir is a protease inhibitor initially developed for HIV treatment that is now used as a pharmacokinetic booster for other antiretrovirals due to it being a cytochrome P450 3A4 enzyme and P-glycoprotein inhibitor. Consequently, ritonavir is of special interest for repurposing in other diseases. It had an important role in battling the COVID-19 pandemic as a part of the developed drug Paxlovid¬Æ¬†in association with nirmatrelvir and has shown effects in hepatitis and other pathogenic diseases. Ritonavir has also shown promising results in overcoming drug resistance and enhancing the efficacy of existing chemotherapeutic agents in oncology. Evidence of cancer repurposing potential was demonstrated in cancers such as ovarian, prostate, lung, myeloma, breast, and bladder cancer, with several mechanisms of action presented. In vitro studies indicate that ritonavir alone can inhibit key pathways involved in cancer cell survival and proliferation, causing apoptosis, cell cycle arrest, endoplasmic reticulum stress, and metabolic stress due to the inhibition of molecules like heat shock protein 90 and cyclin-dependent kinases. Ritonavir also causes resistant cells to become sensitized to anticancer drugs like gemcitabine or docetaxel. These findings indicate that repurposing ritonavir, either on its own or in combination with other medications, could be a promising approach for treating various diseases. This is particularly relevant in cancer therapy, where ritonavir repurposing is the central focus of this review.",['Healthcare Provider']
78995b81-5ca9-4da1-a48f-cf823f7d4448,dennisxhu,Dennis X.Hu,"Chief Executive Officer, Drug Hunter",1462d8e0-2ee6-45f2-8f05-90025a76f4c9,"Boston-Area Drug Hunters!!

Amazing to be back in the heart of biotech last week in the Boston area.

Despite the industry headwinds of the last few years, there‚Äôs never been more palpable excitement about the incredible science exploding across the industry.

Thank you to all of those who joined us for dinner Monday evening Michael Ellis, Chris Helal, Markus Haeberlein, Dafydd Owen, Scott Edmondson, Brian Aquila, Laura Akullian D'Agostino, Joseph Duffy, Richard Chesworth, John Tallarico, Alessandro Boezio, Daniel La, Kenneth Duncan, Janeta Popovici-Muller, Chris Yates, Srinivasa Karra, Meredeth McGowan, Atli Thorarensen, Yuan Hu 

I loved hearing about inspiring favorite molecules from the group, from ground-breaking drugs like boron-containing Velcade, splicing modulator risdiplam, and Paxlovid of COVID fame, to emerging clinical candidates with blockbuster potential.¬†It made me nostalgic to hear natural products like ecteinascidin that inspired folks early on in their careers. Inspiring to see the passion for chemistry very much alive decades into everyones‚Äô careers!

From next-generation CNS medicines, to RNA-targeting molecules, to induced proximity to achieve the impossible, there are so many opportunities, and it‚Äôs great to see so much enthusiasm within the community in all settings - biotech, large pharma, and investors alike.

Thank you Lewis Pennington, Matthew Hesse, Shaima Qunies, and Nicole Lyons (Taylor) from our team for making this week's events possible.

For our 11 incredible site visit hosts - too many thank you‚Äôs to fairly include in a single post - so to be continued!!","['Healthcare Provider', 'Pharmaceutical Representative']"
4ad572f4-b236-43f8-8b46-1a22fdf4e4c3,mark-anthony-jabigo-2a073915b,Mark AnthonyJabigo,RPh üá®üá¶ üáµüá≠ Critical Care | Hospital | Community | Oncology | Compounding | Health Informatics Enthusiast,9bc3ae8f-6207-4433-b4af-f81c055c8c30,"Pharmacists: Leading the Way in Healthcare

Pharmacists are more than medication dispensers; they are frontline healthcare providers offering consultations for minor ailments and prescribing necessary medications. 

From administering vaccines and medications like Prolia to managing diabetes and respiratory care, supporting smoking cessation, conducting COVID-19 assessments, and prescribing Paxlovid, pharmacists are embracing expanded roles with dedication and expertise.

As trusted primary care providers, pharmacists improve patient outcomes and healthcare accessibility through essential consultations and safe, effective medication administration. Proud to be part of a profession that continually adapts to meet our communities' evolving needs! üíäüíâüë©‚Äç‚öïÔ∏èüë®‚Äç‚öïÔ∏è

#HealthcareAdvocates
#FilipinoGlobalTalent
#PharmacyLeader
#üáµüá≠üá®üá¶Pharmacist","['Healthcare Provider', 'Pharmaceutical Representative']"
803eff5b-9a5e-478e-9feb-cb157c55cb92,hillel-wayne,HillelWayne,Formal Methods | Software Engineering | Software History,c8cd6e3c-edb5-4a1a-9afb-1c07f9c3d7c1,"Super secret 10x software engineering tip: don't get COVID.

And if you do get COVID, don't happen to be taken a medication that's contraindicated for Paxlovid.",['Patient']
44ade019-817b-4c03-8568-b8c4bd77739c,neurolgysleepmed,SenthilR.,Neurology and Sleep Medicine,7f1a40d8-a497-475c-9ba7-981c7a4bf30e,"‚ÄúAfter I spent more than 50 years chasing and fighting viruses, one fought back and nearly took me down. I speak of the West Nile virus, delivered by the deadliest animal on the planet ‚Äî the mosquito.

I didn‚Äôt get infected during any of my international trips over the years, but most likely while I was outside my home in Washington, D.C. In mid-August I was feeling weak and exhausted, but attributed it to a recent bout with Covid-19. Though I had tested positive for Covid over a month prior, I had experienced a rebound of symptoms after taking the treatment Paxlovid. Perhaps I was still experiencing lingering symptoms that would eventually resolve.

Not so. Instead, I began to experience unexplained, severe fatigue and exhaustion culminating in my admission to a hospital on Aug. 16, delirious and incoherent with a temperature of 103 degrees. I remember little of the five and a half days that I spent in the hospital except that I had never felt so ill in my life. My physicians assumed that I had sepsis and treated me with antibiotics. After several days, my fever subsided, and I was discharged on antibiotics without a clear diagnosis. That changed the next day when blood tests revealed that I had West Nile virus.

There is no treatment for West Nile virus disease, and I was left to deal with its toll on my body. It was terrifying. I could not swing my legs over the side of the bed to sit up without help from my wife and three daughters. I could not stand up without assistance and certainly could not walk. A very scary part of the ordeal was the effect on my cognition. I was disoriented, unable to remember certain words, asking questions of my family that I should have known the answers to. I was afraid that I would never recover and return to normal.

Fortunately, over a period of a few weeks slow improvement began. I was able to walk with a walker and then without any assistance. Now I can walk a few miles per day with only minimal fatigue, and my cognitive issues have completely resolved. I am on my way to a total recovery, but it has been a harrowing experience‚Ä¶.‚Äù",['Healthcare Provider']
c92aa896-0743-4237-bbb8-9210ce7b82b0,michaelboivin,MichaelBoivin,"Pharmacist Consultant, CME Developer - CommPharm Consulting",dcbe1b54-12ee-4803-a241-c020f73a02b7,Lack of Paxlovid Use in Older Adults: Data from the US showing that the highest risk groups for hospitalization and death from COVID-19 are not receiving outpatient antivirals.  It reduced the risk of severe outcomes in this patient group.  How can we improve this?,['Pharmaceutical Representatives']
0fef1cc0-9cb5-472e-9450-4b00b51deac8,george-niles-mekeel-rn-7b139414,George NilesMekeel RN,"Pro-Public Health & Pro-Science RN Activist in Portugal. Passionate Advocate for DEI, Global Health Equity, Disability, Aging, Human, Migrant & Refugee Rights, Racial, Social & Environmental Justice.",a1c99f32-604f-4d82-87fb-58418a2faaa0,"""Lack of debates/ smearing scientists who disagreed
COVID killed 1.2 million Americans and injured millions more. It‚Äôs not over yet. It was going to be bad no matter what, but according¬†one¬†study¬†estimated:
That at least 232,000 deaths could have been prevented among unvaccinated adults during the 15 months had they been vaccinated with at least a primary series.
None of this bothered pro-infection doctors. In his article¬†Pubic Health Should Lose Your Trust, Dr. Vinay Prasad excoriated public health officials not because they failed to blunt COVID‚Äôs impact, but rather because they tried to hard to do so. He wrote:
Trust is justified based on how an organization or system performs. And the truth is, the entire public health apparatus, failed. In addition to that, leaders at FDA and NIH and CDC engaged in lies and propaganda. As such, they should lose your trust, and without serious reforms you should not return the trust of these organizations.
Those are harsh words. Dr. Prasad listed several reasons why not to trust public heath and none of them had to do with those 1.2 million deaths. His reasons were:¬†natural immunity counts for nothing, masking efficacy, vaccine-myocarditis, Paxlovid, and one size fits all booster recs. All of these measures were intended to limit COVID‚Äôs damage, and whatever their flaws, none of them are as bad as dying of COVID. Yet these are the only things that concerned Dr. Prasad.""    Jonathan Howard, MD","['Healthcare Provider', 'Regulator']"
a9853911-c9bd-49a5-b3fa-62dfa0206f4d,jamescallahancic,JamesCallahan,"Supervisor, Community Health, Infection Prevention and Control at Michael Garron Hospital (formerly Toronto East General Hospital)",415b4c2b-2e87-403d-81aa-f2c0f626b112,"Welcomed the opportunity to present & discuss antiviral administration for COVID-19 in LTC at Women's College Hospital NLOT & LTC+ Learning Community today.

Paxlovid or Remdesivir? Who, when and how?

Nurse-Led Outreach teams are play a pivotal role in preventing avoidable hospitalization during respiratory season.

Nicole (& Yvonne!) knocked this one out of the park",['Regulator']
f4ee422a-0f5c-4e94-b807-3c57eea09534,emilyhardy,EmilyHardy,"Writing & Development Teacher, Consultant & Script Doctor‚†Ä‚†Ä‚†Ä ‚†Ä Former VP/Dev Exec for TV Lit Mgr/EP",0ffa4f41-8350-4d49-8e60-ab1e4818bc30,"Cut! Back to one.

I was so excited to launch my manager class. But... Covid-19. I was taken down for a while. Paxlovid saved the day, but recovery was rough and my energy has been slow to return.

So I wasn't able to promote my class, or prepare my lesson materials,¬†etc. I've wrestled mightily with my deeply-ingrained ""the show must go on"" ethos, but ultimately the healthier and happier plan is to postpone, and relaunch¬†later in the year. I don't want to shortchange my existing clients and mentees (or myself), to chase after a class I haven't even taught yet, just so I can prove to myself that I'm not a quitter.

Many thanks to everyone who expressed interest in taking my class, and everyone who's spread the word or lent their support. The class will happen, and it will be awesome, it just won't be in October.

Please stay tuned for updates, take care and happy holidays to all who are celebrating this month.

Yours truly,

Emily Hardy
Hollywood Swiss Army Knife
www.hwoodsaknife.com
@hwoodsaknife","['Healthcare Provider', 'Regulator']"
9825eb2d-9844-4dd5-8f3d-40521143cd46,jones-quinn,QuinnJones,CIO | CTO | VP of IT | Director of IT | Software Engineer | Builder of High Performing Agile Teams | Innovative Servant Leader | Engagement Expert | Balancing Strengths and Strategic Goals,e83804ae-e49a-4451-abdb-d58708166cf8,"Wait 1 second...is anyone else experiencing DeJaVu?

Are internet streaming services coming full circle back to what we had before we ""cut the cord"" and dropped cable TV?

Time is money, and most of us have moved to Prime and Netflix to eliminate ads we don't care about and waste our time.

Before streaming services, it's why many of us recorded our shows on devices or the good old VCR to fast-forward through commercials.

Also, is it just me, or does anyone else cringe when they hear, ""If you get COVID, PAXLOVID?""

The side effects and disclaimers are 2X longer than the drug pitch.

NO, I don't want to take a drug for restless leg syndrome if the possible side-effect is death.  

My legs can ""boogie oogie oogie"" ""all night long"", and perhaps my Fitbit will show some extra steps to start the day.","['Healthcare Provider', 'Regulator']"
fa35ef73-6c4b-468d-9b3e-9b293164845e,charleslewis3,CharlesLewis III,Journalist. Artist. Critic. Performer. Author. Smarty-pants.,755c6f9b-4d20-468d-b97b-9c8b666ea7f3,"With the latest variant developing a resistance to Paxlovid, you should get your updated booster NOW. (Check BayPLS if uninsured). The latest from Violet Blue:
#MaskUp üò∑ #SocialDistance ‚ÜîÔ∏è #GetVaxxed üíâ #GetBoosted üíâ","['Regulator', 'Patient']"
e55376a7-022c-462b-8502-9716cce0bdb5,dr-shana-charles,"ShanaCharles, PhD, MPP","Associate Professor of Public Health at CSU Fullerton; Councilmember, Fullerton City Council, District 3; Chair, Legislative Committee, Orange County Mosquito and Vector Control District Board of Trustees",cbc82fe4-4cbc-42e0-9e47-820d71dec230,"My Council comments at the end of last night‚Äôs meeting came right after sunset, which is on the last day of 5784. I don‚Äôt usually write out what I‚Äôm going to say in advance, but this time I had some things I needed to express. So here they are, and may 5785 be a year of renewal and healing.
*******************************************
Good evening, everyone. Thank you for being here, and thank you to all who made public comments. It‚Äôs been a tough week in my family, as my elderly parents in San Diego both got COVID for the first time even after getting the new vaccine, which thankfully made it more mild. Neither was hospitalized, but it‚Äôs been difficult. So I encourage everyone again to get the new COVID vaccine and to wear a mask in public if you are immunocompromised, and if you get COVID to ask your doctor about paxlovid, which also reduces severity.

To take an even more serious note, this is the time of year when Jewish people look back, because our new year¬†starts tomorrow night, with Rosh Hashanah. And normally I would just say happy new year, but this year, I am finding it incredibly difficult to grapple with. It is not for local officials to speak on foreign affairs, but I must - and here I have to say that I speak for myself only.

One year ago, after¬†October 7th.¬†I was not ok. In the following weeks, the support from everyone here in Fullerton sustained me. Attending a vigil at Temple Beth Tikvah with Mayor Dunlap, Councilmember Whitaker, and Councilmember Zahra was incredibly healing. I remember in particular having honest and meaningful conversations with Councilmember Zahra, and the peace that both of us felt in standing in unity here at home against any forms of violence. We held a peaceful candlelight vigil at CSUF, with both the Muslim Dumas and Jewish Kaddish prayers, and it was attended by the entire community, including both Chief Radus and Chief Frisbee, which helped us all feel supported and safe. Seeing the billboards in Fullerton made me proud of my community. 

But today‚Äôs news of spreading violence‚Ä¶this is worst possible way to start the year 5785. While everyone has the right to speak freely, I hope that¬†as the anniversary of¬†10/7¬†approaches, people will use their voices to condemn violence in any form.

I‚Äôm going to end with something I wrote years ago, in a quieter time in the world, when I had just reconnected with being Jewish. I was just about to travel to Jerusalem for the first time in my life. And I wrote it about the word ‚ÄúShalom.‚Äù It‚Äôs called Complete.

Complete¬†
We're told as children that Shalom means Peace or a way to say Hello. Goodbye. But I learned here, in my home, in my community, that instead Shalom means Complete. Shalom means Wholeness and Fulfillment. Shalom means Peace flowing, because we have found Shalom here, in our homes and our communities with each other, our spiritual sisters and brothers.

May our search for Completeness and Wholeness be fulfilled for us all in this new year.

Thank you.","['Healthcare Provider', 'Regulator']"
0485505e-05c9-4080-9abc-21c548d82312,dim-velkov-tonev-b591a5266,Dim VelkovTonev,25 years within Hepatology and Virology clinical development,d6f8db83-e811-4b84-adaf-7e997ea3f33d,SarsCov2 Resistance emergence after Paxlovid treatment,['Healthcare Provider']
05cc4303-52e9-4cbe-bedf-ef8866860750,brian-ung,"BrianUng, PharmD, MS",Autoimmune Patient Advocate | Pharmacist | Market Access Professional | Health Economics & Outcomes Researcher,cdb338c0-896d-4300-aac6-32797aba06a5,"The past month has been quite a journey.

After some personal and business travel, I returned home and tested positive for Covid. While my respiratory symptoms were mild and improved with Paxlovid, I soon faced intense stomach discomfort. As things escalated, I found myself in the ER. Initial tests raised concerns, and within hours, I was in surgery, undergoing a procedure that resulted in the removal of over a meter of my small intestine.

Recovery was a gradual process, as I had to reintroduce both liquids and solid foods and regain my physical strength. Throughout this time, I shared my experience with family and friends, whose support was nothing short of incredible.

Thanks to the amazing community around me, we raised over $10,000 for the Walk to End Lupus Now in Los Angeles! Right after my surgery, I was uncertain if I could participate, but this past Saturday, I proudly joined Team Ungstoppable at the opening ceremony and was able to complete the walk!

I‚Äôm taking my recovery one day at a time and feel grateful for my support system during these challenging moments. I'm also thankful I sought medical attention when I did, and I encourage everyone to prioritize their mental, physical, and emotional health. Remember, you know your body best!

#lupus #lupuswarrior #malelupuswarrior #lupusawareness #autoimmunedisease #scleroderma #patientadvocacy","['Healthcare Provider', 'Pharmaceutical Representative']"
da36fffb-10dc-47cb-8640-b76898bbcf69,mdmensah,"George A.Mensah, MD, FACC, FCP(SA) Hon","Director, Center for Translation Research and Implementation Science at NIH/National Heart, Lung, and Blood Institute",576e876b-9e52-47a5-bb91-c03157dcb7a7,"In a nationally representative survey of 1,430 US adults in July 2023, a majority of respondents (85%) had no or low awareness of Paxlovid, including 31% who had never heard of it. Even among those who were aware of the drug, many held misperceptions about its effectiveness (39%), adverse effects (86%), and requisite timing (61%) that could lead to underuse. Lower awareness and misperceptions were more common among underserved populations who might benefit most from #Paxlovid access (including adults unvaccinated against #COVID19, those with lower levels of education, and #Black and #Hispanic or #Latino adults). @NIH Community Engagement Alliance (CEAL) NHLBI ‚Äì Implementation Science National Heart, Lung, and Blood Institute NIH Clinical Center (CC) https://lnkd.in/eB5xvpw5",['Regulator']
726b9d8c-401e-4351-a2f1-1afd3515258c,cjlipowski,Christopher JLipowski,"Healthcare Occupational Health and Safety Professional / Principal, Pinnacle Enterprises Canada",e4cad5e7-5b62-4993-8a98-d521201f3b85,"COVID rapid tests may be trickier to find at pharmacies this fall. Here's what you need to know; ""Some experts are calling for widespread testing as temperatures dip and cold and flu season ramps up""; ""Montreal pharmacist Aleck Brodeur just got a shipment of COVID-19 rapid tests. Ever since the temperature¬†has been dropping, more people have wanted to buy them, he says.¬†
""They go out so fast. We always have to order some every day, and we keep increasing the supply that we order, but they're still all going,"" he said.¬†
He expects this shipment ‚Äî 13 kits in total ‚Äî to be gone by the end of the day. In¬†Quebec, there were 3,882 new laboratory-confirmed cases of COVID-19 between Sept. 15 and Sept. 21.
Unlike last fall, Brodeur doesn't have free rapid tests to hand out. The federal government stopped providing free COVID rapid tests to provinces and territories in May.¬†
In a statement to CBC News, a spokesperson for Health Canada said it is no longer procuring rapid tests en-masse. The agency also says there are no plans to replenish the federal inventory after it is depleted.""; 
NOTE: it‚Äôs not COVID it‚Äôs COVID-19 that is the proper terminology. There are many other unrelated COVID diseases.¬†
I would like to go on record, that our government‚Äôs, provincial and in particular the Federal Government completely disregarding the safety and health of Canadian elder citizens, e.g. those over 65, which can become severely impacted by being infected and developing COVID-19 disease. It is well established that the most vulnerable segment of our society to the severe impact of COVID-19 are the elderly. As a Canadian over 70 years old, I believe we need to sue the Government for criminal negligence by not providing the COVID-19 test. Example: My wife went to BC a few months ago to a medical conference. She came home and was asymptomatic for the infection. Two days after her arrival she tested positive for infection. The the following day I test positive for the infection. Since we don‚Äôt have a family physician as he retired at the beginning of the pandemic I had to convince our pharmacist to provide us Paxlovid, the leading effective medication for treating this infection during the first five days. As a result we both recovered and did not develop the cytokine storm which typically is the point where a patient develops severe respiratory symptoms and as is well known most elders will suffer and die during the second week of the ""Disease Covid-19"". I believe the Canadian government is demonstrating lack of respect nor care concerning our elder citizens and a class action law suite should be considered - CJL); Jennifer Yoon¬†¬∑¬†CBC News¬†¬∑¬†Posted: Sep 29, 2024","['Healthcare Provider', 'Regulator']"
726b9d8c-401e-4351-a2f1-1afd3515258c,cjlipowski,Christopher JLipowski,"Healthcare Occupational Health and Safety Professional / Principal, Pinnacle Enterprises Canada",33ed815c-004c-4e21-a610-26bb56b35b1a,"Episode 166: Infectious Diseases Roulette; ""September 19, 2024
In this episode, Dr. Osterholm and Chris Dall cover the latest infectious disease news on topics including H5N1, mpox, measles, and polio. Dr. Osterholm also answers an ID query on updated COVID-19 vaccines and NOTE THIS! - ""gives his thoughts on a controversial study on Paxlovid.""; - CIDRAP - Center for Infectious Disease Research & Policy, Research and Innovation Office, University of Minnesota, Minneapolis, MN:","['Healthcare Provider', 'Regulator']"
e6ad8ce5-332a-4aaf-9a52-6954f6a7de84,bahman-onaghŸ´-phd-72bba73b,BahmanOnaghŸ´ PhD,"Biotechnologist, Qualified Person in NAT laboratory",67af9e47-f35f-4019-8d70-ca6831409e1d,"Description:
Case studies of 20 successful FDA-approved drugs, from biological rationale to clinical efficacy studies and state-of-the-art applications.
 Chemistry and Pharmacology of Drug Discovery illustrates how chemistry, biology, pharmacokinetics, and a host of disciplines come together to produce successful medicines, discussing a total of 20 drugs that are all FDA-approved post 2021‚Äïsome of which are first-in-class and revolutionary.
 The four sections in this book cover Infectious Disease, Cancer Drugs, CNS Drugs, and Miscellaneous Drugs. Each chapter covers background material on the drug class and/or disease indication and key aspects relevant to the discovery of the drug, including structure-activity relationships, pharmacokinetics, drug metabolism, efficacy, and safety.
 This book is contributed to by various veterans and well-known experts in medical chemistry, many of whom discovered the drugs they reviewed, leading to tremendous quality and depth of insight.
 Some of the drugs covered in Chemistry and Pharmacology of Drug Discovery include:
 Nirmatrelvir (Paxlovid with Ritonavir), a 3-chymotrypsin-like protease inhibitor for treating SARS-CoV-2 infection.
 Doravirine (Pifeltro), a third-generation non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
 Oteseconazole (Vivjoa), a CYP51 inhibitor for treating recurrent vulvovaginal candidiasis, and Rimegepant (Nurtec ODT), a CGRP antagonist for treating migraine
 Ciprofol (Cipepofol), a Œ≥-Aminobutyric acid receptor agonist for induction of anesthesia, and Ozanimod (Zeposia), an S1P receptor antagonist for treating multiple sclerosis.
 Deucravacitinib (Sotyktu), a first-in-class deuterated TYK2 inhibitor for the treatment of plaque psoriasis.
 Chemistry and Pharmacology of Drug Discovery serves as an excellent and highly authoritative learning resource for medicinal, organic, synthetic, and process chemists as well as research scientists in lead optimization and process development.",['Healthcare Provider']
af6018d1-a1b3-490e-9c60-955a55484587,manoj-kumar-chettiar-15315a30,Manoj KumarChettiar,"Senior Warehouse Supervisor | Material Management, Inventory Control",e18d96e5-3a65-4822-ad08-66235ba3f6a0,Role of Healthcare Companies in the Economic Growth of India,['Regulator']
05531b2b-bc56-4e91-a397-5660082d985f,ianmmarks,IanMarks,"Managing Director, Strategy & Solutions, at Amazon Web Services (AWS) | Driving healthcare transformation via strategic, science-backed innovation",85f083d7-9832-421e-9162-57afb361d6ea,"üß† Uncovering Drug-Resistant COVID Variants in Immunocompromised Patients

Recent findings from Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University, and the National Institutes of Health highlight a crucial development in our battle against COVID-19. Their study, published in Nature Communications, reveals that immunocompromised individuals can harbor and potentially spread antiviral-resistant variants of SARS-CoV-2.

üî¨ Study Insights: 
‚óæ Certain immunocompromised patients treated with antivirals like Paxlovid and remdesivir developed resistant strains of the virus, continuing to shed these variants for months. 
‚óæ One identified variant showed resistance to both Paxlovid and remdesivir, raising concerns about the transmission of these resistant strains to the broader population.

üåü Implications: This study underscores the need for tailored treatment strategies for immunocompromised patients to prevent the emergence and spread of resistant COVID-19 variants. It also stresses the importance of continuous surveillance and possibly combining therapies to combat these challenges effectively.

üîó https://lnkd.in/gaxEEzzB

#COVID19 #PublicHealth #Immunotherapy #WeillCornellMedicine #NIH #ViralResistance",['Regulator']
8b7d78d9-8079-453c-a32c-7fdf4258eac0,anusha-konathala-9aa9ab143,Anushakonathala,"üöÄFounder of InspiresAndInnovateüìö | KYC/AML Analyst @ Revolut | Digital Marketing Expert | E-book Author, Writer & Self Publisher | Blogger & website Developer""",01b38fa5-a674-4801-be20-38644c7598f3,"üîî New Newsletter Release: Updates on Global Pharmaceutical Regulatory Changes! üåçüíä
Stay ahead of the game with the latest insights on FDA, EMA, and other key regulatory bodies' changes that are shaping the pharmaceutical industry. From accelerated drug approvals and COVID-19 treatment updates to new environmental risk guidelines and post-Brexit frameworks, this issue covers it all!
In this newsletter, I discuss:
Recent updates from the FDA on gene therapies and opioid regulations
The EMA's latest initiatives, including the Pharmaceutical Strategy for Europe
New post-Brexit guidelines from MHRA and evolving regulations in China and Canada
Whether you‚Äôre a pharmaceutical professional or just interested in how global regulatory changes impact healthcare, this is a must-read for staying informed! view more blogs on our website https://lnkd.in/dt5hNG4T
üìñ Read the full newsletter here
Let‚Äôs discuss how these shifts are impacting the pharmaceutical landscape and your business. Feel free to share your thoughts!
#PharmaceuticalRegulations #FDA #EMA #MHRA #Healthcare #GlobalRegulations #DrugDevelopment #PharmaIndustry #InnovationInPharma",['Regulator']
9750fe4c-99f5-43dc-bbf3-9e0cbf45e8da,becroldan,"BecRoldan, Ph.D.",Freelance Science Writer,923607c1-3245-4890-b646-aa0418e7ce8f,"In my second profile for C&EN's Trailblazer Issue, Carlos A. Martinez shares the story of how he used enzymes, aka nature's catalysts, to make a key starting material for Pfizer's COVID-19 antiviral, Paxlovid. He's been creatively using enzymes in major scale-ups at Pfizer since he started in their first biocatalysis group in 2001. Read more üëá (Available in English, Spanish, and Portuguese)",['Healthcare Provider']
7fe3ef2b-8984-4ea6-91ef-306ebab3049a,mohammad-ashori-md,MohammadAshori MD,Direct Primary Care @ Dr. Ashori,26614e90-02f6-4d9c-80c7-abe3b5c968cc,"""Drug prices are high because we have to spend so much money on the FDA prices. We need to recuperate those R&D costs in the marketing phase of the drugs."" 

And, yet, Paxlovid made it through the FDA process rather seamlessly with an impressively high drug cost. 

Same can be said for certain vaccines.",['Healthcare Provider']
face6018-0019-4db4-a59f-3e4641cddbc4,amber-nigam,AmberNigam,basys.ai | Building the Operating System for Healthcare | TEDx Speaker,eda05220-c85f-48d4-816f-471204d9fce5,"What‚Äôs Wrong with Healthcare?

I recently spoke with a former healthcare executive who tested positive for COVID, and his experience highlights some systemic issues we need to address:

1. *Misinformation*: Despite being on blood thinners, he was advised to take Paxlovid without further questions. While some on blood thinners have taken Paxlovid safely, it could have caused harm. Shouldn‚Äôt health systems ask the right questions?

2. *Access to Treatment*: A major health system in Boston didn‚Äôt have Remdesivir and refused to refer him elsewhere, even though another hospital had it. He made a few calls and got what he needed. But what about those without such connections?

3. *Logistical Failures*: At a new hospital, they initially told him he could only get two infusions because the third fell on a Saturday. Thankfully, it was resolved, but what if two infusions weren‚Äôt enough?

Sounds familiar?",['Regulator']
a969313e-ed0b-4d14-9f0d-fc2ba1a07e8d,mahmoud-alsayes,MahmoudAlsayes,Teaching Assistant at AASTMT,10d07bfe-fa48-47da-ba2a-b8e1121192b6,"Thrilled to share that I recently attended the 3rd International Conference & Exhibition on Pharmaceutical and Healthcare Sciences (PHS 2024).
It was a pleasure helping hard workers, young researchers Malak M. Essam El Din, Marwa R. Barakat and Shaza A.Ashour through out the research process.
Our poster entitled ""Computational screening of Remdesivir analogues as potential dual acting SARS-CoV-2 protease inhibitors"" was selected as one of ideal posters for oral presentation.
Special thanks to my brilliant teammate dr. Menna Ayman.
I am grateful to my inspiring mentor Assoc.¬†Prof. Botros Beshay  for guidance and supervision.
#PHS_2024
#Insilico_Drug_Design
#Computational_Screening",['Healthcare Provider']
87d0e538-b4cd-4ada-9c6d-93c6eb167cd5,giuseppe-giannini-33a470b,GiuseppeGiannini,Medicinal Chemistry - Project Leader; Technology Innovation & External Platforms presso Alfasigma - parla di #scienze #farmaci #farmaceutico #ricerca #innovazione #sociale,fad39e99-7197-40e0-9150-0aded2771aab,"ORGANOCATALYSIS BEHIND THE PROGRESS OF THE ECOLOGICAL ASYMMETRIC SYNTHESIS OF ANTIVIRAL DRUGS

What do drugs like Remdesivir (antiviral), Letermovir (anti-cytomegalovirus), Oseltamivir and Zanamivir (anti-influenza), Efavirenz (anti-HIV/AIDS), Ruxolitinib (anti-tumor) have in common?

They are all chiral molecules. Medicinal chemists are constantly struggling to find increasingly efficient solutions for the scale-up of chiral molecule synthesis processes.

In this minireview, published by Everton M. da Silva, et al. in Pharmaceuticals, summarizes the contribution of organocatalysis to the progress in the greener asymmetric synthesis of antiviral drugs.

#greenchemistry #organocatalysis #asymmetricsynthesis #antiviraldrugs #medicinalchemistry","['Healthcare Provider', 'Regulator']"
262648ec-0e15-4dda-af7c-730deba6b667,colton-mock,ColtonMock,Sales Specialist at LGC Standards,7249d5d3-6f21-41da-bb36-0b667f4027e5,"‚ö†Ô∏è Researchers have been warned to closely monitor mutations that mean the SARS-COV-2 virus could become resistant to leading antiviral drugs.

> Two US studies say the virus is developing strains that are resistant to both remdesivir and nirmatrelvir - particularly in immunocompromised patients already treated with those drugs.

> One also found that the resistance mutations may be able to spread between patients ‚Äì potentially posing a threat to disease management and control in the future.

üî¨ LGC Standards provides a wide range of research tools for antiviral and antiretroviral medicines: https://okt.to/PyNhzm

As well as distributing SARS-Cov-2 genome products from ATCC in Europe and Africa: https://okt.to/39MIYK

üìúLearn more about the study in Medical Xpress: https://okt.to/MAjyiK

#AntiviralDrugs #COVID19 #ResearchChemicals",['Pharmaceutical Representative']
92a29828-d77a-4530-b814-9f02e2f81257,kimberly-morgan-62510441,KimberlyMorgan,Account Manager: Pacific Northwest and Mountain States Region,cf5f5007-e8e6-430e-a3ac-09b1c3f9fdfc,"ü¶†Two studies from the US say the SARS-COV-2 virus is evolving strains that show resistance to leading #AntiviralDrugs remdesivir and nirmatrelvir, particularly among immunocompromised patients who have received these treatments. 

> One also found that the resistance mutations may be able to spread between patients ‚Äì potentially posing a threat to disease management and control in the future.

> Careful monitoring is therefore needed, although most of the mutations are currently detected at low levels and revert back to their original form - meaning they are unlikely to spread widely.

üî¨ LGC Standards provides a wide range of research tools for antiviral and antiretroviral medicine. Explore more: https://okt.to/iHscE1

#COVID19 #ResearchChemicals","['Healthcare Provider', 'Pharmaceutical Representative', 'Regulator']"
53603dba-ed08-4cea-a891-2c96418bdc7c,porcellatoengineering,BradPorcellato,The Heavy Equipment Directory,2e149858-0ca2-4b03-ad84-7653691ff8d7,"EXCLUSIVE: Military Whistleblower Shares his Motivation for Releasing the Explosive ‚ÄúThe Remdesivir Papers‚Äù Report https://t.co/0QFOGsqIbk

  ‚Äî Brad Porcellato (@BradPorcellato)
  Oct 4, 2024

October 04, 2024 at 10:06AM

via Twitter https://lnkd.in/dNnJJtK",['Regulator']
53603dba-ed08-4cea-a891-2c96418bdc7c,porcellatoengineering,BradPorcellato,The Heavy Equipment Directory,e80238ee-9aae-4b25-9350-595159f6aaba,"The Remdesivir Papers: Did Service Members Deserve to Die? https://t.co/8ene7YA9lP

  ‚Äî Brad Porcellato (@BradPorcellato)
  Oct 4, 2024

October 04, 2024 at 08:05AM

via Twitter https://lnkd.in/dNnJJtK",['Regulator']
53603dba-ed08-4cea-a891-2c96418bdc7c,porcellatoengineering,BradPorcellato,The Heavy Equipment Directory,88467a08-77ca-4353-8f39-12c41b461f77,"RT @JMPhelpsLC: The Remdesivir Papers...coming to The Gateway Pundit as early as tomorrow. Be on the look out.

  ‚Äî Brad Porcellato (@BradPorcellato)
  Oct 4, 2024

October 03, 2024 at 08:45PM

via Twitter https://lnkd.in/dNnJJtK",['Regulator']
bef891c3-107b-4e11-ac87-7680240755ba,kianarastegar,KianaRastegar,Veterinarian | DVM,fd24be17-00c7-4b66-bd21-5f1ad3ea9afb,"An 11-month-old male Scottish fold who presented to the clinic with pyrexia, lethargy, anorexia, icterus, pale mucous membranes, uveitis and hypopyon. 
Abdominal ultrasound showed a characteristic medullary rim sign in both kidneys. His A/G ratio was calculated at 0.46 (normal range 0.6-1.5) and GGT levels were measured at 14 IU/L (normal range 1-7).  

Treatment was started with GS-5734 (Remdesivir) at 15 mg/kg for one week, and then 10 mg/kg for the following two weeks, diluted in 0.9% saline and given slowly IV over approximately 30 minutes (per Coggins et al. 2022). Ophthalmic prednisolone was prescribed to control uveitis. Fever subsided after only five days of treatment. 
After reaching an A/G ratio of 0.57, treatment was switched to GS-441524 (with non-effusive disease with CNS signs, 10-12 mg/kg q24h is recommended). The animal received GS-441524 for 50 days as daily subcutaneous injection. Lethargy and hypopyon quickly resolved after initiation of the new treatment. After 50 days on GS-441524, an A/G ratio of 0.67 was achieved and steady weight gain was observed.
The animal was sent home with oral GS-441524 tablets, to be administered once daily for two weeks (10 mg/kg). He has since gained more weight, and his A/G ratio has stabilized.",['Healthcare Provider']
b5c95f74-3930-46d0-83a6-f57697750d14,bright-brobbey-74a595176,BrightBrobbey,Leadership|| Security Analyst|| Communication || Diplomat|| Political Analyst,0ba9957e-dbb9-4ce9-bcc4-a302cc4c124d,"The COVID-19 pandemic, caused by the SARS-CoV-2 virus, began in late 2019 and rapidly spread worldwide, leading to a global health crisis. The virus primarily spreads through respiratory droplets, making it highly contagious, and can cause severe respiratory illness and complications, particularly in vulnerable populations. By 2020, many countries faced overwhelming health systems, lockdowns, and widespread economic disruptions as they worked to contain the spread.

Efforts to curb COVID-19 have evolved significantly since the pandemic‚Äôs early stages. Key strategies include:

Vaccination: The rapid development and global rollout of COVID-19 vaccines have been one of the most significant tools in curbing the pandemic. Vaccines from manufacturers like Pfizer-BioNTech, Moderna, AstraZeneca, and Johnson & Johnson have proven effective in reducing severe illness, hospitalizations, and deaths.
Testing and Diagnostics: Increased testing capacity allowed for early detection and isolation of cases, preventing further transmission. At-home tests and rapid antigen tests helped people identify infections more easily.
Public Health Measures: Initially, social distancing, mask-wearing, quarantine, and travel restrictions were key measures to reduce transmission. These were widely adopted globally, though policies varied by region.

Treatment Advances: Over time, medical treatments for COVID-19 improved. Antiviral drugs, such as remdesivir, and corticosteroids, like dexamethasone, have been used to treat severe cases. In addition, antibody therapies became available, helping reduce mortality and recovery time.

Global Coordination: Organizations like the World Health Organization (WHO) and initiatives like COVAX played important roles in coordinating responses, distributing vaccines to low-income countries, and monitoring virus mutations.

Public Awareness: Information campaigns and education have helped the public adopt preventive measures and make informed health decisions.
Despite these efforts, the virus continues to circulate and mutate, creating variants that sometimes evade immunity from previous infections or vaccinations. As a result, many countries are focusing on long-term management rather than elimination, treating COVID-19 as an endemic disease. Regular vaccinations, enhanced public health surveillance, and healthcare preparedness are key to managing it moving forward.",['Regulator']
c78e92d9-7155-4b29-b2ad-4a855770d0b9,lucas-bialousow-6421b0176,LucasBialousow,Ph.D candidate in biomedical sciences,fe8c43d8-a0f8-414b-8c22-c02f911d0213,"Excited to share that a paper I contributed to was recently accepted for publication! I collaborated with Menny Benjamin in the Hamann group, where we synthesized and purified molecules with strong antiviral potential against SARS-CoV-2. These molecules demonstrated low toxicity and mutagenicity, and their ability to inhibit SARS-CoV-2 activity was comparable to the current treatment, Remdesivir. I‚Äôm hopeful that this class of natural product-derived inhibitors might one day reach the clinic! Here is the link to access the publication: https://lnkd.in/edA_kRag: https://lnkd.in/edA_kRag",['Healthcare Provider']
7f0c91d1-891a-48da-9013-f0e1ab411199,williameades,"WilliamEades, MS",PhD Candidate | Pharm Sci,76839da3-6f39-4519-8cd1-9ac7112ca0fd,"Looking back at our work on ""Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids,"" published in Current Drug Metabolism, I'm filled with pride about the impact it continues to make.

In this study, we explored how CES2 inhibitors, like remdesivir and sofosbuvir, can protect against the gastrointestinal side effects of irinotecan‚Äîa widely used but challenging chemotherapeutic agent. Our findings lay the groundwork for safer cancer treatments by reducing adverse intestinal effects, highlighting a potential pathway to improve patient quality of life.

Grateful for the incredible team behind this achievement and excited to see where this research leads next!

Read the article here: https://lnkd.in/g6Wk2kGh

#ResearchImpact #CancerTherapies #DrugDevelopment #PharmaceuticalScience #HealthInnovation",['Healthcare Provider']
3b6cb357-c17d-4c1d-b1b0-2d219774568d,melkamu-adigo-54066421b,MelkamuAdigo,Public Health Specialist |Vaccine Safety | AEFI Monitoring |Pharmacovigiliance|iSCM Specialist|Cold Chain Management| Humanitarian Logistics and Health Supply Chain|Technical Advisor |Project management|,ce33cac0-2188-4e83-b234-aadc262c13e7,"The #BLACK_SWAN_PHILOSOPHY (Nassim Nicholas Taleb; economist and statistician) and Adverse Drug Reaction
Any drug prescribed or self- medicated medicine can expose the patient to the risk of mild (minor) or serious adverse drug reactions. It is the fact that, drug safety an area where there is notorious risk and uncertainty. ¬†Post marketing surveillance or pharmacovigilance helps prevent, manages, and monitor adverse drug reactions. This can be practiced at health facilities, individually through clinical practice involving patients and prescriber.
From the above theory, adverse drug reactions can be classified as #white, #grey, or #black swans.
#White_Swans:¬†are well-described and known adverse drug reactions 
Psychiatric effects of hydroxychloroquine (during the COVID-19 pandemic lock down
#Black_Swan: Unpredictable effects (event) have a major impact on patients and populations, yet come as a surprise because we have not been able to calculate the probability of these rare adverse reactions using clinical drug evaluations or data from clinical trials.
¬†Example: the risk of thrombosis and thrombocytopenia from non-replicating adenovirus vector-based COVID-19 vaccines. 
#Grey_Swan: are unexpected because they were not reported in clinical trials, but thanks to pharmacovigilance it would be detected from pharmacological knowledge (pharmacodynamics of the drug effects, drug mechanism of action, history of drugs, pharmacokinetics, and pharmaco-genetics) and would help predict and prioritise potential pharmacovigilance signals 
Example of remdesivir (when marketed and used for COVID-19) and serious bradycardia 
Therefore, Pharmacovigiliance systems should be able to handle detect the ‚Äúblack swan‚Äù events¬†which have major impact on public health and patients.
#Refernces
UMC. How can the ‚ÄòBlack Swan Theory‚Äô help us Prevent Adverse Drug Reactions? Report. September 2024
#EthiopianFDA, #UMC, #ETL_Pharmacovigiliance Center, #MedicineSafety","['Healthcare Provider', 'Pharmaceutical Representative', 'Regulator']"
3308d520-7e74-4156-bc23-847de3a809a4,ryan-chen-ph-d-mba-3780a4143,"RyanChen, Ph.D. MBA",Product Marketing Team Lead | Life Science | AI & Cheminformatics in Drug Discovery,0ab44d1c-4efd-47d9-aad3-b86ad05e34fb,"Proud to share XtalPi‚Äôs latest case study on solid-state research, which highlights the strengths of our AI-powered Crystal Structure Prediction (CSP) platform. In drug development, finding the most stable polymorph is critical, especially when R&D timelines are tight and material availability is limited.

Our Solid-State Research team quickly determined the most stable Remdesivir anhydrate form using an integrated experimental and AI-driven approach‚Äîdelivering results twice as fast as standard polymorph research methods. This accelerated process ensures a more reliable path for drug product development.

Kudos to our team for their dedication to advancing the science of polymorph screening!

#XtalPi #CrystalStructurePrediction #SolidStateResearch #Innovation","['Healthcare Provider', 'Pharmaceutical Representative', 'Regulator']"
4fb62c48-5e4a-448e-840c-4cce3afce6d4,chrisnial,ChristopherNial,Watching How Climate will Change Health @FINNPartners | Rotarian | dog dad | whack-a-mole expert | keen listener | defiant optimist despite evidence to contrary,009d3fbf-7e8c-4e20-a2a6-fc23452d6fb5,"üóû ¬†Adult vaccination offers immense economic and societal benefits, with a return of up to *19 euros for every euro invested*. Yet, increased investment and community-led initiatives are crucial to improving uptake and promoting global health equity, particularly in underserved populations.

üóû Rwanda's rapid critical care response, innovative vaccine trials, and proactive leadership significantly reduced the fatality rate of the Marburg virus outbreak to 24%, marking a milestone in African healthcare.

üóû Northern India faces worsening air pollution, as crop burning, firecrackers, and local emissions contribute to hazardous air quality. This has prompted the Supreme Court to demand government action despite ineffective measures.

Gil Bashe, Mark CHATAWAY, Richard Hatzfeld, Darren Jones, Aman Gupta

#globalhealth #impact #policymakers #thoughtleaders",['Healthcare Provider']
8a33071e-0129-4882-8118-b8bb35d99d98,faseeh-mangi-68069456,FaseehMangi,Pakistan Bureau Chief at Bloomberg,e1ab11f1-087f-4213-b8cf-cb21c784ccb4,"After 64 years, business group Ferozsons comes back to Pakistan stock exchange today to list one of its companies. Here's its backstory

Ferozsons is better known as a publishing house that began more than 130 years ago in 1894 as one of the largest publishing houses in then India.

During partition, most of the healthcare facilities was on India's side. The family decided to set up one of the first pharmaceutical factories in Pakistan back in 1950s. It then became the first pharma listed company at that time.

During Covid, the company manufactured remdesivir and is now going to produce a new powerful prevention option for HIV with Gilead Sciences. The twice-yearly HIV prevention shot has prevented almost all HIV cases in studies.",['Regulator']
3.03E+14,akhil,akhil,Patient Advocate,e1ac11f1-087f-4213-b8cf-cb21c784ccb4,Grateful for the support of my #healthcare community. You are not alone!,['Patient']
adf818bd-1c44-430b-a8a6-240dfdc7df4e,saif,Name 4,Patient Advocate,306nfb81-db27-4edf-8519-03f01cb873ca,Seeking advice on navigating the healthcare system as a patient with #healthcare,['Patient']
1e049933-8bfe-4b77-a118-12b0d1f87988,riyaz,riyaz,Patient Advocate,c21d991e-82e6-48be-8788-f13494b1274a,"Grateful for the support of my patient community. Together, we can make a difference!",['Patient']
54en0a55-216d-434b-a9db-760726808072,roshan,roshan,Patient Advocate,a217a09d-126a-4dde-90db-f5e5ed9dcedf,Raising awareness about the impact of #patientadvocacy on mental health,['Patient']
cbe3c68d-0206-4105-b696-adf1029103e1,hufez,hufez,Patient Advocate,da60105e-62ad-4c95-8abe-e59b2459ae87,Advocating for increased funding for #healthcare research,['Patient']
ed1dc723-cde7-48af-8283-cf06635ecc8e,andrew,andrew,Patient Advocate,cdehab25-8983-4bf6-9507-2f0c8ead4253,Seeking advice on managing #chronicillness while living with chronic illness,['Patient']
5489a0a55-216d-434b-a9db-760726808072,azela,azela,Patient Advocate,0ab44e1c-4efd-47d9-aad3-b86ad05e34fb,"Grateful for the support of my patient community. Together, we can make a difference!",['Patient']
d73739b0-d443-4ba4-963b-57de2862a7de,amit-misra-1035526,AmitMisra,Pharmaceutics and Pharmacokinetics Division at CSIR-Central Drug Research Institute,6b1ca166-a7bb-4485-b898-4fe979f4b940,"Siva and Hasham were the prime movers behind our attempt to contribute to the COVID-19 effort. We'd wanted to work on Remdesivir, but it seemed cruel to deprive patients of the best hope so that we could test it in animals. Windlass donated Favipiravir, and we used the simplest possible methods to formulate a DPI. No funding agency was willing to support us, so we used CDRI funding. The paper also went through several rounds of rejection because we used no fancy methods-- a mortar and pestle, the pride of pharmacists since ages, didn't meet the approval of editors of high-impact journals....https://rdcu.be/dXkdk",['Pharmaceutical Representative']
49e5c3f9-d378-41b4-94a7-2df66c875907,pipemanradio,"Dean K.Piper, CST","Owner, Creator, Influencer, Master Marketer, PR, Publicity, Speaker, Trainer, Coach, Published Author, Radio Personality/Podcaster at Talk 4 Media",9a953ebc-486f-4012-857f-4bf7b632db93,"'Remdesivir Papers' allege that the controversial drug was used to treat service members which led to 601 deaths.

Intentional is broadcast live at Tuesdays, Wednesdays, Thursdays 2PM ET and Music on W4HC Radio ‚Äì Health Caf√© Live (www.w4hc.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com). Intentional TV Show is viewed on Talk 4 TV (www.talk4tv.com).

Intentional Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.","['Healthcare Provider', 'Pharmaceutical Representative', 'Regulator']"
3f8142ee-211b-4d64-9973-de6197e97400,marcela-de-la-rossa-bennesch,MarcelaDe la Rossa-Bennesch,Clinical Research Expert | Clinical Trial Specialist | Passionate about Advancing Medical Science,5a8509be-1908-4158-8ca5-2e95299ea950,"Bringing some hope to people who need the most !

In collaboration with the World Health Organization, Rwanda is testing two treatments: Remdesivir, previously used for COVID-19, and MBP091, an antibody specifically designed to combat Marburg.
This is a notable development for global health, and a reminder of the importance of continuous innovation and collaboration in fighting infectious diseases.

For more details on the current Marburg Virus outbreak and ongoing efforts to control its spread, check out the latest update from the WHO : https://lnkd.in/edYg6PgA

#MarburgVirus #ClinicalTrials #GlobalHealth #InfectiousDiseases #PublicHealth #WHO #MedicalInnovation #Filovirus #Remdesivir #AntibodyTherapy #RwandaHealth #EpidemicResponse #MedicalResearch","['Healthcare Provider', 'Pharmaceutical Representative', 'Regulator']"
bfb631d6-f221-4bf8-ab93-07f93a2568fc,wangeci-gatei-1759025,WangeciGatei,"Director, Division of Global Health Protection, Tanzania at Centers for Disease Control and Prevention",8dac7f1a-e0fe-4797-9aec-941d88c39496,"Gilead announced today that it will donate approximately 5,000 vials of remdesivir to the Rwanda Medical Supply in conjunction with the Ministry of Health of the Republic of Rwanda and the Africa Centers for Disease Control for emergency use in response to the Marburg Virus Disease (MVD) outbreak.",['Regulator']
54ea0a55-216d-434b-a9db-760726808072,yashar-mateen,"YasharMateen, MBA","Corporate Strategy - Biotech | Software Developer | Java, Python, AL/ML",6f2a28fb-5003-42bf-ba46-0e2ad147a5ee,"AI is changing clinical trials for the better. In my latest article, I explore how it's improving data management, patient recruitment, and drug discovery 
#AI #ClinicalTrials #Healthcare #Biotech #Pharma","['Healthcare Provider', 'Regulator']"
2d578b45-f7d4-4f78-bba6-149bb464b18f,krishnamaringanti,KrishnaM.,"Chemist. Founder, Sustainable Environment for Earth Foundation (SEEF). Managing Partner - Colabs Pharma Pvt Ltd., G1 Nutrients, and Colabs Strategic Materials and Ordnance Systems (COSMOS)",020ceffd-175e-419e-8644-93c0a4c9d3b2,"Vaccine lies are True Lies. We ought to savour them. Remember them. Unknown percent of the young who took vaccines die with cardiac arrest. Then we can blame their rich companies! It actually happened with #EarnstandYoung of India.  A young girl died, and we've seen so many judgemental idiots jumping their gun!","['Healthcare Provider', 'Pharmaceutical Representative', 'Regulator']"
1e949933-8bfe-4b77-a118-12b0d1f87988,obiebukadavid,Obi EbukaDavid,Founder & CEO Autogon AI || YC Alumni || Forbes/GSE 2020 || IEEE Member (AI won't replace you. Someone using AI will),213e88eb-d270-48a6-b588-bd12c7aa1638,"üî¨ Small Wins Against COVID-19 with Big AI Innovations üî¨

COVID-19 treatments like Remdesivir and Paxlovid have helped, but our AI model is taking it further even beyond for SARS-CoV-2 and beyond. We‚Äôve generated molecules with higher potential across multiple protein targets, showing promising results in binding affinity and drug-like properties.

From small victories on COVID-19 to amazing breakthroughs on other disease targets, Medgnosis GenAI continues to innovate. Explore more reports at https://medgnosis.ai/

Here is our latest press release: https://lnkd.in/d2i2-Xf2

#COVID19 #AIinHealthcare #DrugDiscovery #MedgnosisAI #ProteinTargeting Pfizer, Moderna, Johnson & Johnson",['Regulator']
1db941fd-ff67-4168-939e-a5e354ca60ca,anil-a-panackal-m-d-s-m-11320833,"AnilA. Panackal, M.D., S.M.","Senior Director, Clinical Project Lead, Clinical Sciences R&D, ID/Vaccines at GSK",3cf517bb-f9db-4b0f-9c5f-cc298e314e26,"Plans to surveil and contain the current Marburg virus outbreak in Rwanda are ongoing. Marburg disease has similar disease manifestations and mortality to Ebola Zaire, to which it is most closely related. The Sabin Vaccine Institute in Washington D.C. has sent emergency doses of its experimental chimpanzee adenovirus (ChAd-3) vector vaccine (a platform originally developed at GSK in collaboration with NIH/NIAID for its Ebola Zaire, Ebola Sudan, and Marburg vaccines ‚Äî which were acquired by Sabin). These will be used for a real-time field ring vaccination trial. Remdesivir will also be used in a separate trial. Stay tuned! #Marburg #viralhemorrhagicfever #ringvaccination #publichealthpreparedness #publicprivatepartnerships

https://lnkd.in/ehx7hdDZ

https://lnkd.in/eUpzGDGK

https://lnkd.in/eTFiVECw

https://lnkd.in/eBupzacA

https://lnkd.in/eqhbPRFZ","['Healthcare Provider', 'Regulator']"
ba702802-2a60-4256-b331-8b37020107b6,arif-nazir-md-690ab541,ArifNazir MD,"Chief Medical Officer, Abode Care Partners",159d9523-f8a0-42fc-8984-fa42cf00e712,"COVID 19 is not the ""thing of past"". It is very truly present and is continuously causing problems for people of all ages, but more for those who are frail and older.

The Journal of American Medical Association provided an excellent overview of its management that continues to focus around prevention via vaccinations and then treatment with antivirals.

Here are a few highlights:

- Adults 65 years and older continue to experience the highest rates of hospitalization and death due to COVID-19, emphasizing the need for therapeutic interventions in this population.
- Increasing the use of COVID-19 treatments to 80% could reduce hospitalizations by 42% and deaths by 51%, yet only 16.5% of high-risk adults have ever received treatment.
-Antiviral therapy should be initiated within 5-7 days of symptom onset in high-risk individuals, especially those aged 65 and older or with comorbidities such as heart disease or diabetes.
- Three antiviral treatments are suggested‚Äînirmatrelvir/ritonavir (Paxlovid), remdesivir, and molnupiravir. Nirmatrelvir/ritonavir and remdesivir have the highest efficacy in reducing severe outcomes.
- Nirmatrelvir/ritonavir interacts with several medications via the CYP3A enzyme, so clinicians should use databases to assess interactions.
- Although rebound of symptoms after antiviral treatment is possible, it has not been linked to severe disease, hospitalization, or antiviral resistance.

Abode Care Partners BrightSpring Health Services Post-Acute and Long-Term Care Medical Association (PALTmed)",['Healthcare Provider']
cbe4c68d-0206-4105-b696-adf1029103e1,hanif-ajari-436790197,HanifAjari,"Director Export Network, Inst. Business & CS at Getz Pharma",a211a09d-126a-4dde-90db-f5e5ed9dcedf,"ASTRAZENECA AND GILEAD SCIENCES: COULD A MERGER CREATE THE WORLD'S LARGEST PHARMA GIANT?

In an industry-shaking move, AstraZeneca, the UK‚Äôs largest drugmaker valued at $140 billion, has reportedly approached Gilead Sciences, an American biopharmaceutical company valued at $96 billion, to explore a possible merger. While the approach was informal, it aimed to gauge Gilead's interest in what could become the largest pharmaceutical merger in history. If successful, the merger would surpass notable deals, such as the $87.6 billion merger between Bristol-Myers Squibb and Celgene Corporation.

This potential merger is likely motivated by the global race to develop Covid-19 treatments. Gilead‚Äôs antiviral drug Remdesivir, proven to shorten recovery time for Covid-19 patients, could generate $7 billion in annual sales by 2022 if stockpiling strategies are adopted. Meanwhile, AstraZeneca is advancing in its development of a potential Covid-19 vaccine. Combining their efforts could cement their dominance in coronavirus treatment.

However, the merger is far from certain. Gilead, a profitable and stable company, has historically shied away from large-scale mergers, favoring smaller acquisitions. With a strong financial standing, the likelihood of Gilead agreeing to a deal remains speculative.

Though difficult to achieve, a successful merger could reshape the pharmaceutical industry and create a global leader in healthcare innovation.

Source: Pharmaceutical Technology, a GlobalData owned brand.",['Regulator']
be058e29-50fd-4f0d-9a37-96ae31a158cd,lippa-goranson-2a1725320,LippaGoranson,Environmental scan and analysis,da5d6c7e-3e6e-4772-b041-02e5674d3888,#Covid19USA #totalitarianism #psychologicalexperiments #psychology #humannature #documentary #movie #film #hospitalprotocol #vaccineinjury #CHD #research #wethepeople #peoplesvoice #authority #healthcare #abuse #treatmentoptions #medicalethics #ethics #Covid19 #remdesivir #ivermectin #hydrocholroquine #integrativemedicine #vitaminC #Vaxxed #Experimenter #historylesson,['Patient']
7936fc62-28a4-4e51-96b9-9213d4ee893b,rayburchett,RayBurchett,Champion for Human Potential,c050a39e-8561-4af8-b314-a382386be3a0,"Must read for comprehending the efforts to deceive, manipulate, and exploit Americans through COVID VAX and Remdemsiver treatment. This article fails to mention the refusal of HCQ and Ivermectin - which we now know to be safe and effective. I experienced this first hand on the civilian side. Confident if I detailed the behavior of medical professionals who forced Remdemsiver on me  I would be removed. https://lnkd.in/gQKgqz8W. Surprised there are not class action lawsuits - this is textbook RICO",['Patient']
ed1dc723-cde7-48af-8283-cf06635ecc8e,jamescallahancic,JamesCallahan,"Supervisor, Community Health, Infection Prevention and Control at Michael Garron Hospital (formerly Toronto East General Hospital)",689a3957-ba80-4d93-a1ca-f63daca27552,"Welcomed the opportunity to present & discuss antiviral administration for COVID-19 in LTC at Women's College Hospital NLOT & LTC+ Learning Community today.

Paxlovid or Remdesivir? Who, when and how?

Nurse-Led Outreach teams are play a pivotal role in preventing avoidable hospitalization during respiratory season.

Nicole (& Yvonne!) knocked this one out of the park",['Healthcare Provider']
50baa80d-978d-4f7a-bf51-d1656354c0fc,dr-atoosa-salimi-61229345,Dr AtoosaSalimi,"Senior General practitioner, MBBS, FRACGP, MHA with specialisation in Public Health and health promotion, Epidemiology,MTOP,NLP,CBT,Diploma of Paediatrics, Diploma Sexual health.",da69105e-62ad-4c95-8abe-e59b2459ae87,"https://lnkd.in/gnPGwP3J

Eighteen volunteers developed infection by qPCR criteria of sustained viral load, one without symptoms and the remainder with mild illness. Infected volunteers showed statistically lower baseline-corrected global composite cognitive scores than uninfected volunteers, both acutely and during follow up (mean difference over all time points = ‚àí0.8631, 95% CI = ‚àí1.3613, ‚àí0.3766) with significant main effect of group in repeated measures ANOVA (F (1,34) = 7.58, p = 0.009). Sensitivity analysis replicated this cross-group difference after controlling for community upper respiratory tract infection, task-learning, remdesivir treatment, baseline reference and model structure. Memory and executive function tasks showed the largest between-group differences. No volunteers reported persistent subjective cognitive symptoms.",['Healthcare Provider']
9675e888-d2af-4277-a84a-97712748cf63,juan-carlos-salamanca-bayena-9648b4152,Juan CarlosSalamanca Bayena,"Medico internista con formaci√≥n especializada. Experiencia en cargos de responsabilidad y altos est√°ndares de calidad. Curioso, innovador, proactivo y creativo. Experiencia en equipos de trabajo multidisciplinarios.",306afb81-db27-4edf-8519-03f01cb873ca,"More evidence for remdesivir's benefit in severe COVID-19.

Prime Campus.",['Healthcare Provider']
63491a19-31ca-43ec-ba3e-d8a300974d06,cjlipowski,Christopher JLipowski,"Healthcare Occupational Health and Safety Professional / Principal, Pinnacle Enterprises Canada",cdeeab25-8983-4bf6-9507-2f0c8ead4253,"TWiV 1152: Clinical update with Dr. Daniel Griffin; ""In his weekly clinical update, Dr. Griffin deep dives into the durability of the antibody response following mpox vaccination, vaccine security, global mpox circulation, the origins of SARS-CoV-2, including a list TWiV episodes and combatting scientific misinformation, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, what do when healthcare workers succumb to SARS-CoV-2 infection, if remdesivir + dexamethasone lowers mortality of hospitalized COVID-19 patients and the finding of how SARS-CoV-2 infection impacts memory and cognition.""; Sep 28, 2024; MicrobeTV: https://lnkd.in/exq9DnMS","['Healthcare Provider', 'Pharmaceutical Representative', 'Regulator']"
78f29041-308e-4511-9373-d9e1fe5a7dbf,ianmmarks,IanMarks,"Managing Director, Strategy & Solutions, at Amazon Web Services (AWS) | Driving healthcare transformation via strategic, science-backed innovation",289f3a09-f0e2-4a51-af37-46c4a32c4ae0,"üß† Uncovering Drug-Resistant COVID Variants in Immunocompromised Patients

Recent findings from Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University, and the National Institutes of Health highlight a crucial development in our battle against COVID-19. Their study, published in Nature Communications, reveals that immunocompromised individuals can harbor and potentially spread antiviral-resistant variants of SARS-CoV-2.

üî¨ Study Insights: 
‚óæ Certain immunocompromised patients treated with antivirals like Paxlovid and remdesivir developed resistant strains of the virus, continuing to shed these variants for months. 
‚óæ One identified variant showed resistance to both Paxlovid and remdesivir, raising concerns about the transmission of these resistant strains to the broader population.

üåü Implications: This study underscores the need for tailored treatment strategies for immunocompromised patients to prevent the emergence and spread of resistant COVID-19 variants. It also stresses the importance of continuous surveillance and possibly combining therapies to combat these challenges effectively.

üîó https://lnkd.in/gaxEEzzB

#COVID19 #PublicHealth #Immunotherapy #WeillCornellMedicine #NIH #ViralResistance","['Healthcare Provider', 'Patient', 'Pharmaceutical Representative', 'Regulator']"
ca6a21b9-5298-4028-b42a-6bbc85601cb6,joseph-m-8886903a,JosephM.,"Manager, PV Governance & Compliance at Sentrex",4d41c89d-7d0d-403d-948a-d30cb7b38107,"#Drugrecalls in rare disease area in 2024

In 2024, there have been significant drug recalls related to #rarediseases. A notable recall involved Veklury (remdesivir), an antiviral drug used primarily to treat COVID-19. 

Gilead Sciences issued a recall in September due to the presence of glass particles in a specific batch of the injectable form. This defect could potentially lead to serious health risks such as vessel blockage and stroke if administered .

Additionally, while there haven‚Äôt been recalls directly tied to rare diseases beyond this, important developments include the approval of Aqneursa (levacetylleucine) and Miplyffa (arimoclomol) for Niemann-Pick disease Type C (NPC). 

These treatments offer new hope for patients with this ultra-rare genetic disorder, although no recalls for these drugs have been reported.","['Healthcare Provider', 'Pharmaceutical Representative', 'Regulator']"
b3efd167-a2e3-4545-94fa-bfb8e67b8110,aomersheriff,Omer SheriffAneez,Director @ Inscribe INC | Transforming Medico-Legal Services | Medical Records Management | APS Summary Services | Litigation Support Services | Mass Tort Cases,c79f3429-a417-4f61-88ef-0d223d9f0faf,"ùêìùê®ùêÆùê≠ùêûùêù ùêöùê¨ ùêö ùê•ùê¢ùêüùêû-ùê¨ùêöùêØùê¢ùêßùê† ùêùùê´ùêÆùê†, ùê°ùê®ùê∞ ùêùùê¢ùêù ùêëùêûùê¶ùêùùêûùê¨ùê¢ùêØùê¢ùê´ ùêûùêßùêù ùêÆùê© ùê¢ùêß ùê•ùêûùê†ùêöùê• ùê≠ùê´ùê®ùêÆùêõùê•ùêû? 

While the world was fighting the COVID-19 infection, Gilead Sciences produced and marketed an injection- Remdesivir to treat hospitalized and non-hospitalized adults and children suffering from the COVID-19 infection.¬†
In September 2022, two Remdesivir lawsuits were filed, but what led to the filing of lawsuits, was it the manufacturer's or the physician's fault? If you‚Äôre new to this case, you may have your doubts. Let me brief it: 

ùêñùê°ùêöùê≠ ùê∞ùêûùêßùê≠ ùê∞ùê´ùê®ùêßùê†? Clinical trials and studies found that Remdesvir did not play any role in curing the infection. Moreover, they found that the injection could lead to acute kidney damage, heart failure, increased liver enzymes, and can be fatal. 

ùêÉùê¢ùêù ùê¢ùê≠ ùê†ùêûùê≠ ùêöùêßùê≤ ùê∞ùê®ùê´ùê¨ùêû? Well, yes. It was found that the patients were not informed or asked for consent before administering the injection. Many people alleged that Gilead made the hospitals prescribe this drug to their patients. 

ùêñùê°ùêöùê≠ ùê∞ùêûùê´ùêû ùê≠ùê°ùêû ùêöùê•ùê•ùêûùê†ùêöùê≠ùê¢ùê®ùêßùê¨ ùê¶ùêöùêùùêû?¬†
‚û° The doctors committed fraud by prescribing the drug to the victims without their knowledge.¬†
‚û° They also failed to explain that the drug is ineffective in treating COVID-19 infection, can be toxic to the kidneys, and can cause death. 

ùêñùê°ùêöùê≠ ùê°ùêöùê©ùê©ùêûùêßùê¨ ùêßùêûùê±ùê≠? A class action lawsuit has been filed against Gilead Sciences, alleging negligence, violation of consumer protection laws, fraud, and strict liability.¬† 

Since it is an ongoing case and there are possibilities of many more lawsuits coming up, I‚Äôm curious to know where this case heads. Surely, medical records are going to play a critical role in these cases. 

Share your thoughts about the case in the comments section.

#inscribe #Lawsuit #MedicalRecordsManagement #RemdesivirLawsuit",['Regulator']
90cf95ec-4ec3-43f9-95cd-06464601f14e,cwhenderson,C.W. H.,"Founder, Journalist, Researcher, NewsRx",ea9b3d42-163d-442c-82e4-bd7a31845b6f,"COVID: A new study of outcomes among more than 33,000 hospitalized COVID-19 patients shows that remdesivir plus dexamethasone administration is associated with lower mortality rates at 14 and 28 days compared with dexamethasone alone, according to findings in Clinical Infectious Diseases attached here in comments.","['Healthcare Provider', 'Regulator']"
90cf95ec-4ec3-43f9-95cd-06464601f14e,cwhenderson,C.W. H.,"Founder, Journalist, Researcher, NewsRx",01b8ffc8-a63e-45c9-bf96-ceb2f68a405c,"COVID: You can get helpful COVID treatments in the hospital. Every person is different and has different needs. But some treatment options include: 

‚ÄîOxygen, given through nasal prongs or a mask
‚ÄîIntravenous (IV) fluids to keep you well hydrated
‚ÄîSteroids, if you have underlying lung conditions
‚ÄîAntiviral medications, like remdesivir
‚ÄîBiologic medications, like vilobelimab or tocilizumab
‚ÄîAnti-inflammatory medications, like baricitinib or anakinra

When you go to the ER for COVID, one of the most important parts of your evaluation will be checking your vital signs. These include your: 

‚ÄîOxygen level (sometimes called ‚Äúpulse ox‚Äù)
‚ÄîBreathing rate
‚ÄîHeart rate
‚ÄîBlood pressure

Depending on your vital signs and physical exam, your care team may also run some additional tests to see how the virus is affecting your body. These tests may include:

‚ÄîX-ray of your lungs to look for signs of pneumonia or fluid
‚ÄîCT scan of your chest to look at the lungs in greater detail or to check for blood clots
‚ÄîElectrocardiogram (ECG) of your heart to look for signs of stress or strain on your heart
‚ÄîBlood tests to check your blood counts, kidney function, and electrolytes

After these tests, you‚Äôll discuss if you‚Äôre safe to continue recovering at home or if you should stay in the hospital for closer monitoring.

What happens when you are admitted to the hospital?

Your care team in the ER will probably recommend you stay in the hospital if:

‚ÄîYou‚Äôre struggling to breathe.
‚ÄîYour oxygen levels are low.
‚ÄîYou‚Äôre struggling to stay hydrated or keep fluids down.
‚ÄîYou have any changes in how alert or sleepy you are, or how coherent you seem.
‚ÄîYou have a medical condition that makes it more likely that your infection will worsen. 

In the hospital, a healthcare professional can monitor you and your symptoms more closely.","['Healthcare Provider', 'Regulator']"
5033348f-3763-4e1c-be63-1cbbbbdccfea,rudi-ringwald-b2862925,RudiRingwald,Owner/President at Black Forest Acres,47d4a448-b283-4045-8e84-e89d6c270206,"New Jersey!¬†Bill A1884, sponsored by Assemblyman Herb Conaway, MD is being heard Monday, September 23, 2024 at 10 AM in the Assembly Health Committee in Trenton.¬†New Jersey residents are encouraged to attend the meeting and give personal testimony.¬†¬†¬†
If this bill passes,¬†A1884¬†will deem the act of disseminating ‚Äúmisinformation‚Äù as professional misconduct for health care professionals and further subject them to disciplinary action. This bill defines ‚Äúdisseminate‚Äù to mean the conveyance of information, in the form of treatment or advice, from a health care professional to a patient under the health care professional‚Äôs care. ‚ÄúMisinformation‚Äù is defined as: ‚Äúany health-related claim of fact that is false and contradicted by contemporary scientific consensus contrary to the standard of care.‚Äù ‚ÄúDisinformation‚Äù is defined as:¬†¬†‚Äúmisinformation that is deliberately disseminated with malicious intent or an intent to mislead.‚Äù
Key Questions Raised:¬†
Are New Jersey legislators attempting to silence healthcare professionals and infringe upon free speech?¬†
Will this bill transform New Jersey into a medical police state, where dissenting medical opinions are punished rather than discussed and further studied?¬†
Haven‚Äôt we learned from the mistakes of the COVID-19 pandemic in that some of the interventions and treatments recommended based on consensus from the medical community turned out to have devastating consequences for patients (ie: intubation and Remdesivir)?
Doesn‚Äôt this bill contradict the fluid and evolving nature of the scientific method?¬†
How will this bill affect medical professionals' use of new treatments or those being used successfully ‚Äúoff-label‚Äù?
Will this bill prevent medical professionals from thinking ‚Äòoutside the box‚Äô when dealing with difficult-to-treat and rare diseases/illnesses?
Will chiropractors, acupuncturists, mental healthcare professionals, social workers be targeted by this bill as well? Will this restrict social workers in sessions with patients' and their ability to speak freely and have open discussions on various topics? This seems like a very slippery slope.
Will practitioners be restricted to only¬†practicing¬†medicine if it is based on ‚Äúcontemporary scientific consensus or following the standard of care?‚Äù¬†
Why would a patient need a second opinion if healthcare professionals would only be able to practice the ‚Äúcontemporary scientific consensus?‚Äù
Will pharmaceutical representatives‚Äô conversations/content also be scrutinized for misinformation/disinformation?
If this bill passes, how will this ‚Äúmisinformation/disinformation‚Äù be enforced?¬†Will healthcare professionals be reported or disciplined for offering advice outside ‚Äúscientific consensus?‚Äù¬†
Who will determine what is considered outside the ‚Äúscientific consensus‚Äù?
Could this bill stifle scientific progress in New Jersey, as it might have prevented questioning about outdated practices like lobotomies?","['Healthcare Provider', 'Regulator']"
9da15c9e-4b93-4957-978f-7f369567a378,amitvn,AmitV.,Senior General Manager | Pharmaceuticals & Chemicals | Global Markets | Exports | Business Development | Strategy | Operations | Marketing | Distribution | Manufacturing,5e067f33-25e5-419a-9231-8dd35b42ab93,"Antimicrobial Resistance (AMR) is not a dreaded fate that awaits us.

No, not at all.

It's happening as we speak.

The Amoxicillins, the Azithromycins, the Fluconazoles, the Levofloxacins. Even the highly selective Linezolid usually reserved for severe infections and methicillin-resistant Staphylococcus aureus (MRSA) infections.

This can also be seen in other parts of the world.

Take for example antimalarial Artemisinin Combination Therapies (ACT) treatments in Africa.

Having lived in West Africa for some time, I remember how people so easily popped an antimalarial at the first signs of flu/ fever like symptoms, least bothered to have a Doctors opinion.

ACTs were OTCs!

On the other side of the spectrum, I have another example. 

Last year I was in Barcelona for CPHI, and had been carrying along a 10 day pretty rough chest infection.

Forgetting for a minute I was in Europe, I popped into one of their beautiful pharmacies and asked for 3 tablets of Azithromycin 500mg.

They all looked at me as if I'd asked for their kidneys.

They immediately asked for the prescription.

In whatever Spanish I knew, I simply had to explain I didn't have one. 

And as per their rules, they refused to serve me - however much I tried to prove my chesty cough to their on-duty manager.

Funnily, I truly felt the respect given to what a prescription drug stands for and how it is dispensed to patients.

Yes, over there, Rx medications are certainly not commercialised as OTCs.

Back to AMRs seen in India.

What do you think are some of the causes?

I can think of a few.

üíä Pharma companies can get really pushy for sales. Imagine branding a double antibiotic FDC simply as an 'antidiarrheal drug'! And please do note that diarrhea has other causes other than bacteria.

üë®‚Äç‚öïÔ∏è The pressure on medical reps to achieve the ludicrous targets easily leads to unethical promotion onto Doctors, in many cases leading to unnecessary prescription and eventually over-consumption of antibiotics.

üè• Hospitals are big businesses in India and we all know how patient can get so easily squeezed financially once they get caught, sorry, admitted. Just imagine how much Remdesivir was administered during Covid and at what cost.

ü©∫  Prescribing habits of DRs should remain ethical and patient centric. Prescribing antibiotics to satisfy MRs and pharma companies is totally unacceptable in the current context.

‚öïÔ∏è Patients asking for and chemists dispensing antibiotics without prescriptions NEEDS to end. 

Now surely, there are many other causes to AMRs.

But the above few are quite critical and we humans, or human greed if you prefer, is responsible.

This is something that can be curbed.

If not eradicated.

Hard-core stringent legislation is what's missing.

Severity of repurcusions and punishments follows in a close second.

Rules need to be set.

Rules need to be followed.

With ethics and discipline. 

A bit like in Barcelona I guess.

#masterplan #pharma #antibiotics #prescription #otc",['Healthcare Provider']
63f8b3d1-0e31-403a-abf5-99352ba67496,fakry-f-mohamed-4275a1117,Fakry F.Mohamed,"Postdoctoral researcher | Virologist (BVM, MSc, PhD) | Fighting SARS-CoV-2, influenza, and other viruses | Passionate about research, collaboration, and teaching.",339ceeb3-878f-447c-a3fe-5d015553bba1,"Check this out!
Chen and Xi¬†reported in their informative article ""Cardiovascular adverse effects of #antiviral therapies for #COVID-19: Evidence and plausible mechanisms.""¬†published in Acta Pharmacologica Sinica¬†(#2024) that some well-known #antivirals against #SARS #CoV2, including #Remdesivir, #Paxlovid, #Molnupiravir, and #monoclonal #antibodies like #tixagevimab and #cilgavimabhave, in addition to #Ivermectin, #Hydroxychloroquine, and #Chloroquine, had severe impacts on the cardiovascular system in direct and indirect ways.",['Healthcare Provider']
bf74a0cc-784a-45f7-841d-b5f0e3b7035c,bilal-shabir-243165262,Bilalshabir,Veterinary Doctor at Pet Point Clinic F10 Islamabad,a31c9f3c-7af8-4904-9764-d5a14706c1b9,"A cat presented with complain of fever, depression , loss of appetite,weight loss, 
abdominal size increases, ataxia, icterus & difficult breathing 
On laboratory test :
leukocytosis & lymphopenia.
hight Globulin protiens.
On Xrays:
pleural and abdominal effusion 
other Lab Test:
yellowish fluid Sample obtained from abdomen Rivalta test performed for FIP and its positive for it.
Dx:
Feline infections peritonitis 
Treatment:
symptomatic treatment given to cat and with use of diuretics also flushing the body 
injection Remdesivir given on daily basis 
after 20 days the size of abdomen decreases 
On Xray there also decreases in pleural and abdominal effusion.",['Healthcare Provider']
37e0205d-c7b6-4ee8-89a9-d3c0f19cba35,mirella-salvatore-1062968,MirellaSalvatore,"MD, FIDSA. Associate Professor of Medicine and Population Health Science. Physician Scientist @ Weill Cornell Medicine/ Clinical and Translational Research/ Respiratory viruses/Vaccines",aa48821d-313f-4c55-a330-8aa8049fe4c0,"I am glad to share our latest work on COVID-19 in the immunocompromised host. We found high rates of resistance, including replicating and transmissible virus carrying double resistance to paxlovid and remdesivir more than 2 months after infection of a immunocompromised host with prolonged infection.",['Healthcare Provider']
012a6594-5a33-4b4d-b064-9a1b1c11aba8,ankita-mishra-1bb21470,AnkitaMishra,Sr. Manager - Content at Avian WE Content Strategy | Storytelling | Corporate Communications | Brand Strategy | Ex-journo,e039f781-c830-4493-80c9-656ce73603fa,"My mother has a habit of safekeeping my #bylines. Time to time she looks up my old author profiles and shares with me my stories she thinks were well-written, relevant or important interviews. She sent me this story back from the time when there was an acute shortage of #Remdesivir. Asked me, ‚Äúwhy did you not tell me that you‚Äôd written this story.‚Äù I told her that honestly I didn‚Äôt even remember this existed. She was clearly shocked and asked again‚Äîhow can I forget about an important interview. I told her, I only remember the circumstances.

The point is, as writers, journalists, or content creators, we often get so consumed by the process, the pressure that we lose sight of the impact of our work. We may forget the stories, but it‚Äôs the situations we document‚Äîcrisis moments, human challenges, experiences that last. This conversation with Maa was a humbling reminder that the written word lives on even when we‚Äôre not looking.

#news #writer #journalist #writing #interview #story",['Patient' ]
